

---

**European Union Risk Management Plan**

Drug Substance	Durvalumab
Version Number	10
Succession Number	3
Data lock point	30 April 2023
Date	See e-signature page

---

---

**EUROPEAN UNION (EU) RISK MANAGEMENT PLAN (RMP)**  
**FOR**  
**IMFINZI™ (DURVALUMAB)**

---

The content of this EU RMP has been reviewed and approved by the Marketing Authorisation Holder's Deputy Qualified Person for Pharmacovigilance (QPPV), as delegated by the QPPV. The electronic signature is available at the end of the document.

IMFINZI™ is a trademark of the AstraZeneca group of companies.

## ADMINISTRATIVE INFORMATION

### Rationale for submitting an updated RMP

This EU RMP (Version 10) has been updated to:

- Add a new indication (*IMFINZI in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with: IMFINZI as monotherapy in endometrial cancer that is mismatch repair deficient [dMMR]; IMFINZI in combination with olaparib in endometrial cancer that is mismatch repair proficient [pMMR]; see Part I:*).

### Summary of significant changes in this RMP

Part I:	Updated to include an additional indication and dosage regimen.
Part II SI:	Epidemiology data relevant to the new indication added.
Part II SIII:	Exposure data in support of the new indication added.
Part II SIV:	Exposure data in support of the new indication added.
Part II SV:	Postmarketing exposure data updated to reflect latest available information.
Part IV:	DUO-E study added as a post-authorisation efficacy study
Part VI:	Updated with the changes outlined above.

### Other RMP versions under evaluation

Not applicable.

### Details of currently approved RMP

Version number:	Version 9
Approved with procedure:	EMA/H/C/004771/II/0057
Date of approval:	12 October 2023

## TABLE OF CONTENTS

TABLE OF CONTENTS .....	3
LIST OF TABLES .....	4
LIST OF ANNEXES .....	7
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS.....	8
I: PART I: PRODUCT OVERVIEW .....	10
II: PART II: SAFETY SPECIFICATION.....	13
II: 1 MODULE SI: EPIDEMIOLOGY OF THE INDICATION(S) AND TARGET POPULATION .....	13
II: 1.1 Lung Cancer.....	13
II: 1.2 Biliary Tract Cancer .....	19
II: 1.3 Hepatocellular Carcinoma .....	22
II: 1.4 Endometrial Cancer .....	26
II: 2 MODULE SII: NON-CLINICAL PART OF THE SAFETY SPECIFICATION	29
II: 2.1 Summary of Key Safety Findings from Non-Clinical Data .....	29
II: 3 MODULE SIII: CLINICAL TRIAL EXPOSURE.....	30
II: 3.3 Exposure to IMFINZI + Tremelimumab + SoC Chemotherapy for Metastatic NSCLC .....	35
II: 3.4 Exposure to IMFINZI (± Tremelimumab) for HCC.....	37
II: 3.5 Exposure to IMFINZI + EP for ES-SCLC .....	39
II: 3.6 IMFINZI Monotherapy Exposure Across Indications.....	40
II: 4 MODULE SIV: POPULATIONS NOT STUDIED IN CLINICAL TRIALS .....	42
II: 4.1 Exclusion Criteria in Pivotal Clinical Studies Within the Development Program.....	42
II: 4.2 Limitations to Detect Adverse Reactions in Clinical Trial Development Programs .....	44
II: 4.3 Limitations in Respect to Populations Typically Under-Represented in Clinical Trial Development Programs.....	45
II: 5 MODULE SV: POST-AUTHORISATION EXPERIENCE.....	46
II: 5.1.1 Method Used to Calculate Exposure .....	46
II: 5.1.2 Exposure .....	46
II: 6 MODULE SVI: ADDITIONAL EU REQUIREMENTS FOR THE SAFETY SPECIFICATION.....	47
II: 7 MODULE SVII: IDENTIFIED AND POTENTIAL RISKS .....	48
II: 7.1 Identification of Safety Concerns in the Initial RMP Submission .....	48
II: 7.1.1 Risk Not Considered Important For Inclusion in the List of Safety Concerns in the RMP .....	48
II: 7.1.2 Risks considered important for inclusion in the list of safety concerns in the RMP.....	50
II: 7.2 New Safety Concerns and Reclassification with a Submission of an Updated RMP.....	52

II: 7.3	Details of Important Identified Risks, Important Potential Risks, and Missing Information .....	52
II: 8	MODULE SVIII: SUMMARY OF THE SAFETY CONCERNS .....	53
II: 8.1	Summary of the Safety Concerns .....	53
III:	PART III: PHARMACOVIGILANCE PLAN .....	54
III: 1	ROUTINE PHARMACOVIGILANCE ACTIVITIES .....	54
III: 2	ADDITIONAL PHARMACOVIGILANCE ACTIVITIES .....	54
III: 3	SUMMARY TABLE OF ADDITIONAL PHARMACOVIGILANCE ACTIVITIES .....	54
IV:	PART IV: PLANS FOR POST-AUTHORISATION EFFICACY STUDIES .....	55
V:	PART V: RISK MINIMISATION MEASURES .....	56
V: 1	ROUTINE RISK MINIMISATION MEASURES .....	56
V: 2	ADDITIONAL RISK MINIMISATION MEASURES .....	56
V: 3	SUMMARY OF RISK MINIMISATION MEASURES .....	56
VI:	PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN FOR IMFINZI (DURVALUMAB) .....	57
VI: 1	THE MEDICINE AND WHAT IT IS USED FOR .....	57
VI: 2	RISKS ASSOCIATED WITH THE MEDICINE AND ACTIVITIES TO MINIMISE OR FURTHER CHARACTERISE THE RISKS .....	58
VI: 2.1	List of Important Risks and Missing Information .....	59
VI: 2.2	Summary of Important Risks .....	59
VI: 2.3	Post-authorisation Development Plan .....	59
VI: 2.3.1	Studies that are Conditions of the Marketing Authorisation .....	59
VI: 2.3.2	Other Studies in the Post-Authorisation Development Plan .....	59
	LIST OF REFERENCES .....	60
VII:	PART VII: ANNEXES .....	74
Annex 4:	Specific Adverse Drug Reaction Follow-Up Forms (Not Applicable) .....	75
Annex 6:	Details of Proposed Additional Risk Minimisation Activities (Not Applicable) .....	76

## LIST OF TABLES

Table I-1	Product overview .....	10
Table II-1	Incident cases of NSCLC, 2018 .....	13
Table II-2	Incident cases of SCLC, 2018 .....	14
Table II-3	Five-year prevalence rate for lung cancer (per 100000), 2018 .....	14
Table II-4	Prevalent cases of Stages IIIB and IV NSCLC and ES-SCLC, 2018 .....	15
Table II-5	Age-adjusted incidence and death rates of lung and bronchus cancer by race/ethnicity in US .....	16

Table II-6	Incidence Rates Reported As Age-Standardised Rates per 100000 person-years by Country between 2008 to 2012.....	20
Table II-7	Estimated Number of Incidence Cases of Liver Cancer and HCC, by Gender and Region, 2018.....	23
Table II-8	Estimated 5-Year Prevalence of HCC Worldwide and by Region, 2018 ...	24
Table II-9	Estimated Number of Deaths due to Liver Cancer, by Gender and Region, 2018 .....	25
Table II-10	IMFINZI: Key Findings from Non-clinical Data.....	29
Table II-11	Summary of Studies Included in the RMP.....	30
Table II-12	Duration of Exposure to IMFINZI (SoC + D and SoC + D + O Arms; DUO-E Study [Overall Period]).....	33
Table II-13	Exposure to IMFINZI by Age Group (SoC + D and SoC + D + O Arms; DUO-E Study [Overall Period]).....	33
Table II-14	Exposure to IMFINZI by Race (SoC + D and SoC + D + O Arms; DUO-E Study [Overall Period]).....	34
Table II-15	Duration of Exposure to IMFINZI (D + Gem/Cis Arm; TOPAZ-1 Study) (N = 338).....	34
Table II-16	Exposure to IMFINZI by Age Group and Gender (D + Gem/Cis Arm; TOPAZ-1 Study) (N = 338).....	35
Table II-17	Exposure to IMFINZI by Race (D + Gem/Cis Arm; TOPAZ-1 Study) (N = 338) .....	35
Table II-18	Duration of exposure to IMFINZI and Tremelimumab (D + T75 + SoC Arm; POSEIDON Study) (N=330).....	36
Table II-19	Exposure to IMFINZI and Tremelimumab by Age Group and Sex (D + T75 + SoC Arm; POSEIDON Study) (N=330).....	36
Table II-20	Exposure to IMFINZI and Tremelimumab by Race (D + T75 + SoC Arm; POSEIDON Study) (N=330).....	37
Table II-21	Duration of Exposure to IMFINZI Monotherapy and in Combination with Tremelimumab (HCC Tumour Pool).....	38
Table II-22	Exposure to IMFINZI Monotherapy and in Combination with Tremelimumab by Age Group and Sex (HCC Tumour Pool) .....	38
Table II-23	Exposure to IMFINZI Monotherapy and in Combination with Tremelimumab by Race (HCC Tumour Pool).....	39
Table II-24	Duration of Exposure to IMFINZI (D + EP Arm; CASPIAN Study) (N=265).....	39
Table II-25	Exposure to IMFINZI by Age Group and Gender (D + EP Arm; CASPIAN Study) (N=265) .....	40

Table II-26	Exposure to IMFINZI by Race (D + EP Arm; CASPIAN Study) (N=265) .....	40
Table II-27	Duration of Exposure to IMFINZI Monotherapy (Pan-Tumour Pool) (N=3006) .....	40
Table II-28	Exposure to IMFINZI Monotherapy by Age Group and Gender (Pan-Tumour Pool) (N=3006).....	41
Table II-29	Exposure to IMFINZI Monotherapy by Race (Pan-Tumour Pool) (N=3006) .....	41
Table II-30	Exposure of Special Populations Included or Not in Clinical Trial Development Programs .....	45
Table II-31	IMFINZI Dosing and Duration of Therapy .....	48
Table IV-1	Planned and Ongoing Post-Authorisation Efficacy Studies that are Conditions of the Marketing Authorisation or are Specific Obligations ....	55

## **LIST OF ANNEXES**

[Annex 4](#) Specific Adverse Drug Reaction Follow-Up Forms *(Not applicable)*

[Annex 6](#) Details of Proposed Additional Risk Minimisation Activities *(Not applicable)*

## LIST OF ABBREVIATIONS AND DEFINITION OF TERMS

<b>Abbreviation/ Special term</b>	<b>Definition/Explanation</b>
ALK	anaplastic lymphoma kinase
AST	aspartate aminotransferase
BCG	Bacillus Calmette-Guérin
BIL	bilirubin
BRAF	activating serine threonine-protein kinase-B-raf kinase
BTC	biliary tract cancer
BMI	body mass index
CCRT	concurrent chemoradiation therapy
CD	cluster of differentiation
CNS	central nervous system
CrCL	creatinine clearance
CTLA-4	cytotoxic t-lymphocyte-associated antigen 4
D	durvalumab
DCO	data cut-off
dMMR	mismatch repair deficient
DNA	deoxyribonucleic acid
EEA	European Economic Area
EGFR	epidermal growth factor receptor
EP	etoposide with either carboplatin or cisplatin
EPAR	European Public Assessment Report
ePPND	Enhanced prenatal and postnatal development
ESMO	European Society for Medical Oncology
ES-SCLC	Extensive-stage small cell lung cancer
EU	European Union
FDA	Food and Drug Administration
GBC	gallbladder cancer
GBD	Global Burden of Disease
HCC	hepatocellular carcinoma
HIV	human immunodeficiency virus
HNSCC	head and neck squamous cell carcinoma
HRQoL	health-related quality of life
IARC	International Agency for Research on Cancer
ICH	International Council for Harmonisation



<b>Abbreviation/ Special term</b>	<b>Definition/Explanation</b>
IgG1κ	immunoglobulin G1 kappa
IHCC	intrahepatic cholangiocarcinoma
imAE	immune-mediated adverse event
iv	intravenous
mAb	monoclonal antibody
MOA	mechanism of action
NCCN	National Comprehensive Cancer Network
NPCR	National Program of Cancer Registries
NSCLC	non-small cell lung cancer
NTRK	neurotrophic receptor tyrosine kinase
O	olaparib
PCI	prophylactic cranial irradiation
PD-1	programmed cell death protein 1
PD-L(1/2)	programmed cell death ligand (1/2)
PL	patient leaflet
pMMR	mismatch repair proficient
Q2W	every 2 weeks
Q3W	every 3 weeks
Q4W	every 4 weeks
QPPV	Qualified Person for Pharmacovigilance
RECIST	Response Evaluation Criteria in Solid Tumours
RMP	Risk Management Plan
SCLC	Small cell lung cancer
SEER	Surveillance, Epidemiology, and End Results
SoC	standard-of-care (chemotherapy)
SmPC	Summary of Product Characteristics
UC	urothelial carcinoma
ULN	upper limit of normal
UK	United Kingdom
US	United States

## I: PART I: PRODUCT OVERVIEW

**Table I-1 Product Overview**

<b>Active substance(s) (INN or common name)</b>	Durvalumab
<b>Pharmacotherapeutic group(s) (ATC Code)</b>	L01FF03
<b>Marketing Authorisation Holder</b>	AstraZeneca AB, 15185 Södertälje, Sweden
<b>Medicinal products to which this RMP refers</b>	One
<b>Invented name(s) in the EEA</b>	IMFINZI
<b>Marketing authorisation procedure</b>	Centralised
<b>Brief description of the product</b>	<b>Chemical class:</b> IMFINZI is a fully human, high affinity, IgG1 $\kappa$ mAb.
	<b>Summary of mode of action:</b> IMFINZI is an immunomodulatory therapy within the pharmacotherapeutic group of the antineoplastic agents, which selectively blocks the interaction of PD-L1 with PD-1 and CD80 (B7.1) while leaving PD-1/PD-L2 interaction intact.
	<b>Important information about its composition:</b> IMFINZI is composed of 2 identical heavy chains and 2 identical light chains, with an overall molecular weight of approximately 149 kDa. IMFINZI contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to complement protein C1q and the fragment crystallizable gamma receptors involved in triggering effector function.
<b>Hyperlink to the Product Information</b>	[Summary of Product Characteristics]
<b>Indication(s) in the EEA</b>	<p><b>Current:</b></p> <ul style="list-style-type: none"> <li>• IMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable NSCLC in adults whose tumours express PD-L1 on <math>\geq 1\%</math> of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy.</li> <li>• IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with ES-SCLC.</li> <li>• IMFINZI in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adults with unresectable or metastatic BTC.</li> <li>• IMFINZI in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations.</li> <li>• IMFINZI in combination with tremelimumab is indicated for the first-line treatment of adults with advanced or unresectable HCC.</li> <li>• IMFINZI as monotherapy is indicated for the first-line treatment of adults with advanced or unresectable HCC.</li> </ul>

**Table I-1 Product Overview**

	<ul style="list-style-type: none"> <li>• IMFINZI in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with:             <ul style="list-style-type: none"> <li>- IMFINZI as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)</li> <li>- IMFINZI in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR)</li> </ul> </li> </ul>
<p><b>Dosage in the EEA</b></p>	<p><b><u>Current:</u></b></p> <ul style="list-style-type: none"> <li>• <u>For locally advanced NSCLC:</u> 10 mg/kg Q2W or 1500 mg Q4W<sup>a</sup> until disease progression, or unacceptable toxicity, or a maximum duration of 12 months<sup>b</sup>.</li> <li>• <u>For ES-SCLC:</u> 1500 mg<sup>c</sup> in combination with chemotherapy Q3W (21 days) for 4 cycles, followed by 1500 mg Q4W as monotherapy, until disease progression or unacceptable toxicity.</li> <li>• <u>For BTC:</u> 1500 mg<sup>g</sup> in combination with chemotherapy Q3W (21 days), followed by 1500 mg Q4W as monotherapy, until disease progression or unacceptable toxicity.</li> <li>• <u>For metastatic NSCLC:</u> <ul style="list-style-type: none"> <li>- <i>During platinum chemotherapy:</i> 1500 mg<sup>d</sup> in combination with tremelimumab 75 mg and platinum-based chemotherapy Q3W (21 days) for 4 cycles (12 weeks).</li> <li>- <i>Post-platinum chemotherapy:</i> 1500 mg Q4W as monotherapy and histology-based pemetrexed maintenance therapy Q4W. A fifth dose of tremelimumab 75 mg alongside IMFINZI dose 6 should be given at Week 16. Treatment should be continued until disease progression or unacceptable toxicity.</li> </ul> </li> <li>• <u>For HCC:</u> <ul style="list-style-type: none"> <li>- IMFINZI 1500 mg<sup>e</sup> administered in combination with 300 mg<sup>e</sup> tremelimumab as a single dose, followed by IMFINZI 1500 mg as monotherapy Q4W, until disease progression or unacceptable toxicity.</li> <li>- IMFINZI 1500 mg Q4W<sup>f</sup>, as long as clinical benefit is observed or until unacceptable toxicity.</li> </ul> </li> <li>• <u>For endometrial cancer:</u> IMFINZI 1120 mg in combination with carboplatin and paclitaxel Q3W (21 days) for a minimum of 4 and up to 6 cycles, followed by maintenance with IMFINZI 1500 mg<sup>h</sup> Q4W as monotherapy (dMMR patients) or in combination with olaparib 300 mg twice daily (pMMR patients), until disease progression or unacceptable toxicity.</li> </ul>
<p><b>Pharmaceutical form(s) and strengths</b></p>	<p>Concentrate for solution for infusion (sterile concentrate). Clear to opalescent, colourless to slightly yellow solution, free from visible particles. Each mL of concentrate for solution contains 50 mg of durvalumab. Each 2.4 mL vial contains 120 mg of durvalumab. Each 10 mL vial contains 500 mg of durvalumab.</p>

**Table I-1 Product Overview**

<b>Is the product subject to additional monitoring in the EU?</b>	Yes
---	-----

- a Patients with a body weight of 30 kg or less must receive weight-based dosing, equivalent to IMFINZI 10 mg/kg Q2W or 20 mg/kg Q4W as monotherapy until weight increases to greater than 30 kg.
- b It is recommended to continue treatment for clinically stable patients with initial evidence of disease progression until disease progression is confirmed.
- c ES-SCLC patients with a body weight of 30 kg or less must receive weight-based dosing of IMFINZI 20 mg/kg in combination with chemotherapy Q3W (21 days), followed by 20 mg/kg Q4W as monotherapy until weight increases to greater than 30 kg.
- d Metastatic NSCLC patients with a body weight of 30 kg or less must receive weight-based dosing, equivalent to IMFINZI 20 mg/kg until weight is greater than 30 kg. Patients with a body weight of 34 kg or less must receive weight-based dosing equivalent to tremelimumab 1 mg/kg until the weight is greater than 34 kg.
- e HCC patients with a body weight of 30 kg or less must receive weight-based dosing, equivalent to IMFINZI 20 mg/kg until weight is greater than 30 kg. Patients with a body weight of 40 kg or less must receive weight-based dosing, equivalent to tremelimumab 4 mg/kg until weight is greater than 40 kg.
- f Patients with a body weight of 30 kg or less must receive weight-based dosing, equivalent to IMFINZI 20 mg/kg Q4W as monotherapy until weight increases to greater than 30 kg.
- g BTC patients with a body weight of 36 kg or less must receive weight-based dosing of IMFINZI at 20 mg/kg in combination with chemotherapy Q3W (21 days), followed by 20 mg/kg Q4W as monotherapy until weight increases to greater than 36 kg.
- h Endometrial cancer patients with a body weight of 30 kg or less during maintenance phase must receive weight-based dosing equivalent to IMFINZI at 20 mg/kg, until weight is greater than 30 kg.

## II: PART II: SAFETY SPECIFICATION

### II: 1 MODULE SI: EPIDEMIOLOGY OF THE INDICATION(S) AND TARGET POPULATION

#### II: 1.1 Lung Cancer

There are 2 distinct histological subtypes of lung cancer: NSCLC and SCLC representing approximately 85% and 10 to 15% of all lung cancers, respectively ([American Cancer Society 2019](#)).

#### Incidence

Worldwide data from the IARC show that lung cancer is the most common type of cancer diagnosed, with 2.1 million new lung cancer cases predicted in 2018 ([Bray et al 2018](#)). The age-adjusted incidence rate of lung cancer worldwide was 22.5 per 100000 with lower rates in women (14.6 per 100000) compared to men (31.5 per 100000), which may be partly attributed to the gender difference in tobacco use. Incidence rates (per 100000) vary geographically, with the highest age-adjusted incidence rate reported in the US (35 in both sexes; 40.1 in males; 30.8 in females), followed by Western Europe (33.9 in both sexes; 43.3 in males; 25.7 in females).

#### NSCLC

The incidence rates of NSCLC are highly variable and depend largely on local smoking prevalence. An overview of incident cases of Stage III unresectable and Stage IV NSCLC, by region, are presented in [Table II-1](#).

**Table II-1 Incident cases of NSCLC, 2018**

	Stage III unresectable	Stage IV	Total NSCLC all stages	Stage III unresectable as % of total NSCLC	Stage IV as % of total NSCLC
United States	39731	75643	181788	21.9	41.6
France	5984	16300	34059	17.6	47.9
Germany	7182	19601	43754	16.4	44.8
Italy	5673	17561	37433	15.2	46.9
Spain	3798	10613	21083	18.0	50.3
United Kingdom	7102	18000	39870	17.8	45.1
Japan	15871	24509	93276	17.0	26.3

Note: The Decision Resources Group utilised different data sources for different countries. NSCLC is defined according to the International Classification of Diseases, Tenth Revision with a diagnosis code C34 excluding cases with the histology codes 8041-8045 for small cell lung cancer.

Source: [Decision Resources Group 2018](#)

## SCLC

The overall SCLC incidence has been decreasing steadily over the last few decades in Western countries ([Oberli et al 2016](#), [Riaz et al 2012](#), [Wang et al 2017](#)). Prior studies reveal a steady decline in rates among males and a stable trend among females in Europe, likely attributable to a reduction in smoking rates. Incidence rates (per 100000) vary by geography and gender (England: 6.0 in males, 4.0 in females; US: 6.4 in males, 5.4 in females; Switzerland: 7.4 in males, 4.0 in females) ([Riaz et al 2012](#), [Wang et al 2017](#), [Oberli et al 2016](#)). Counter to the trend in Europe, rates among women in Spain have increased annually by 3.8% during 2008 to 2012 ([Linares et al 2016](#)).

Across Japan, the US, and EU 5 (UK, Germany, France, Italy and Spain), the number of incident ES-SCLC cases was projected to be lowest in Spain (2615) and highest in the US (21609) in 2018 ([Table II-2](#)).

**Table II-2 Incident cases of SCLC, 2018**

Geography	ES-SCLC	Total SCLC all stages	ES-SCLC as % total SCLC
United States	21609	27083	80%
France	2862	4217	68%
Germany	5480	8945	61%
Italy	2950	4459	66%
Spain	2615	3988	66%
United Kingdom	3619	5340	68%
Japan	4625	7860	59%

Note: The Decision Resources Group utilised different data sources for different countries. SCLC is defined according to the International Classification of Diseases, Tenth Revision with a diagnosis code C34 and histology codes 8041-8045 indicating small cell lung cancer.

Source: [Decision Resources Group 2018](#)

## Prevalence

In many regions, the pattern of lung cancer prevalence rates (over 5 years) generally follows that of incidence rates, except for Northern Europe, North America, and the US, where prevalence rates for males and females are converging ([Bray et al 2018](#)). Across Europe, the highest prevalence was reported for Western and Northern European countries; 84.1 and 76.0 per 100000, respectively. The prevalence of lung cancer in the US and Asia in the same year was 78.3 and 26.6 per 100000, respectively ([Table II-3](#)).

**Table II-3 Five-year prevalence rate for lung cancer (per 100000), 2018**

Region/country	Males	Females	Total
World	34.1	21.6	27.9
North America	77.4	78.7	78.1
United States	78.4	78.3	78.3

**Table II-3 Five-year prevalence rate for lung cancer (per 100000), 2018**

Region/country	Males	Females	Total
Europe	86.3	48.7	66.9
Central and Eastern Europe	77.5	28.7	51.7
Northern Europe	75.4	76.6	76.0
Southern Europe	94.4	42.1	67.6
Western Europe	98.4	70.2	84.1
Asia	33.6	19.1	26.6

Note: Age standardised to the world population. Lung cancer is defined in GLOBOCAN based on the International Classification of Diseases, Tenth Revision as a diagnosis with the code C33-34 (including trachea).

Source: [Bray et al 2018](#)

### NSCLC

The number of prevalent (re-staged, to allow for movement by stage over time, over 5 years) cases of Stages IIIB and IV NSCLC was estimated at 51032 and 541691, respectively, in the US, Japan and EU 5 ([Kantar Health 2018](#)) (Table II-4).

### SCLC

The estimated number of prevalent (re-staged, 5-year) cases of ES-SCLC was estimated at 92340 in the US, Japan and EU 5 ([Kantar Health 2018](#)) (Table II-4).

**Table II-4 Prevalent cases of Stages IIIB and IV NSCLC and ES-SCLC, 2018**

Country	Stage IIIB NSCLC	Stage IV	ES-SCLC
United States	17388	202933	34913
France	3662	44095	8038
Germany	4692	56689	12505
Italy	4084	50029	5924
United Kingdom	3849	50446	7758
Spain	2343	27980	6201
Japan	15014	109519	17001

Note: Standard prevalence assumes all those diagnosed at a given stage remain in that stage. Restaged prevalence corrects for this and estimates the number of patients currently in a specific stage during a given time frame.

Source: [Kantar Health 2018](#).

### **Demographics of the population in the authorised indication – age, gender, racial and/or ethnic origin and risk factors for the disease**

The age-adjusted incidence and death rates for all lung and bronchus cancers by race-ethnicity groups in the US for 2011 to 2015 are presented in [Table II-5](#).

**Table II-5 Age-adjusted incidence and death rates of lung and bronchus cancer by race/ethnicity in US**

Race/ethnicity	Incidence rates (2009-2013)		Death rates (2010-2014)	
	Male	Female	Male	Female
All races	63.8	47.8	53.8	35.4
Non-Hispanic White	68.6	54.8	56.3	39.0
Non-Hispanic Black	81.2	47.9	65.1	33.5
Asian/Pacific Islander	45.9	28.0	31.2	17.8
American Indian/Alaska Native	45.4	31.2	35.3	23.7
Hispanic	34.1	23.2	26.5	13.3

Note: Data are based on the US SEER registries. Rates are per 100000 population and age adjusted to the 2000 US standard population. Non-Hispanic White and Non-Hispanic Black are not mutually exclusive of Hispanic origin. Source: [Siegel et al 2017](#).

### NSCLC

Across the US, Japan and EU 5, the estimated numbers of Stage III unresectable NSCLC cases diagnosed among persons aged  $\geq 65$  years was more than double the number in adults aged 20 to 64 years (72.4% of cases of Stage III unresectable) ([Decision Resources Group 2018](#)).

Males are more likely to be diagnosed with NSCLC; 62% of incident unresectable Stage III NSCLC cases and 60% of incident Stage IV NSCLC cases occur in males ([Decision Resources Group 2018](#)). Risk factors for NSCLC include tobacco, environmental tobacco smoke, family history of lung cancer, genetic factors, occupational factors and radiation risk, air pollution, and inflammation and infection.

### SCLC

According to 2018 statistics from Decision Resources Group, the majority of new cases of extensive-stage SCLC occur in patients aged  $\geq 65$  (70.8%) and males (60.9%) ([Decision Resources Group 2018](#)).

Important risk factors for SCLC include tobacco use, gender, age, family history of lung cancer, and environmental factors such as air pollution and exposure to asbestos ([Alberg et al 2007](#), [Straif et al 2009](#), [Gray et al 2009](#), [Katanoda et al 2011](#), [Cao et al 2011](#), [Hales et al 2012](#), [Lissowska et al 2010](#)).

## **The main existing treatment options**

### NSCLC

The standard of care for patients with Stage III unresectable NSCLC is definitive platinum-based CCRT. IMFINZI may be given as consolidation therapy for patients with



performance status 0 to 1 who do not experience disease progression after 2 or more cycles of CCRT ([NCCN 2018](#)).

Other options are a weekly paclitaxel/carboplatin regimen or pembrolizumab for the first-line treatment of patients with Stage III, unresectable NSCLC who are not candidates for CCRT.

Sequential chemotherapy/radiation therapy or radiation therapy alone is appropriate for frail patients unable to tolerate CCRT.

In Stage IV NSCLC, preferred first-line systemic treatments are based on the presence of specific molecular characteristics, including activating EGFR mutations (osimertinib, afatinib, erlotinib, gefitinib, and dacomitinib), ALK rearrangements (alectinib, brigatinib, lorlatinib, ceritinib, and crizotinib), ROS1 rearrangement (entrectinib, ceritinib and crizotinib), BRAF V600E mutation (dabrafenib plus trametinib, and vemurafenib), NTRK gene fusion (larotrectinib and entrectinib), MET exon 14 skipping (capmatinib and tepotinib), and RET rearrangements (selpercatinib and pralsetinib) ([NCCN 2021b](#)).

Platinum-based systemic therapy in combination with anti PD-1/PD-L1 agents (eg, pembrolizumab and atezolizumab) is the standard of care for patients who do not have mutation positive tumours. Regimens containing pembrolizumab are preferred for those with tumours that express PD-L1. These include pembrolizumab + cisplatin/carboplatin + pemetrexed for adenocarcinoma and large cell subtypes, and pembrolizumab + carboplatin + paclitaxel (or albumin-bound paclitaxel) for squamous cell carcinoma. For patients with tumours expressing high levels of PD-L1 (>50%), pembrolizumab monotherapy is an option ([NCCN 2021b](#)).

### SCLC

In ES-SCLC, platinum-based chemotherapy (cisplatin or carboplatin in combination with etoposide, irinotecan), are common first-line options ([NCCN 2019](#)). Atezolizumab in combination with etoposide and carboplatin was recently approved by the FDA for the first-line treatment of ES-SCLC ([FDA 2019](#)).

Consolidative thoracic radiotherapy is beneficial for selected patients with extensive-stage disease and good response to systemic therapy ([NCCN 2019](#)). Extensive-stage patients who also respond to systemic therapy may also receive PCI. If the patient has extensive disease with localised symptomatic sites, palliative radiotherapy should be administered directly to the symptomatic sites ([NCCN 2019](#)). Brain metastases should be treated with whole brain radiation therapy.

### **Natural history of the indicated condition in the untreated population, including mortality and morbidity**

There are very limited inter-regional statistics on mortality for the worldwide target population. The highest age-adjusted mortality rate (per 100000) for lung cancer in 2018 was reported from Western Europe (24.6), followed by Central and Eastern Europe (23.6), and Southern Europe (22.7).

#### Morbidity:

##### *NSCLC*

Patients with NSCLC commonly experience multiple symptoms, both lung-specific (eg, cough, shortness of breath, chest pain, hoarseness, and haemoptysis) and systemic (loss of weight or appetite, feeling tired or weak) ([American Cancer Society 2019](#), [Walter et al 2015](#)).

##### *SCLC*

Patients with SCLC experience a short duration of symptoms prior to diagnosis, with lesions usually inducing cough, wheezing, deep chest pain, and dyspnoea caused by airway obstruction ([American Cancer Society 2019](#)).

#### Mortality:

##### *NSCLC*

Median survival data from international randomised controlled trials of nonresectable locally advanced NSCLC following chemoradiation ranges from 12 to 26 months ([Spina et al 2013](#)).

According to the National Cancer Institute's SEER data, the median survival for Stage III NSCLC patients who did not have surgery (during the initial 6-month period) diagnosed in 2010 to 2014 was 11 months for males and 13 months for females ([Spina et al 2013](#)). Furthermore, SEER reported a 5-year survival rate of 14% for Stage IIIA lung cancer patients. According to data collected from SEER cancer registries in 2008 to 2014, the 5-year survival for patients diagnosed with lung cancer that has spread to distant sites is just under 5% ([Siegel et al 2017](#)).

##### *SCLC*

The prognosis of ES-SCLC is poor with a median overall survival of <10 months ([Wang et al 2017](#), [Alvarado-Luna and Morales-Espinosa 2016](#)). Overall survival has remained relatively unchanged since the 1970s ([Wang et al 2017](#), [Mäkitaro et al 2002](#)).

## **Important co-morbidities**

### NSCLC

Common co-morbidities in patients with NSCLC include: chronic pulmonary disease, diabetes, cerebrovascular disease, peripheral vascular disease, myocardial infarction, congestive heart failure, renal disease, and non-lung malignancy (Nilsson et al 2017, Wang et al 2012, Edwards et al 2014).

Comorbidities associated with sequelae from concurrent chemoradiation and Stage III unresectable NSCLC include oesophagitis, radiation pneumonitis, pneumonitis, pulmonary fibrosis, anaemia and neutropenia (Rodrigues et al 2004, Mazon et al 2010, Rowell and O'Rourke 2004).

### SCLC

Common comorbidities in all patients with SCLC (regardless of stage) include hypertension, cardiovascular and cerebrovascular diseases, diabetes (Aarts et al 2015), and chronic obstructive pulmonary disease (Lee et al 2018a, Maxwell et al 2016).

Common side effects associated with chemotherapy include neutropenia, nausea and vomiting, fatigue, anaemia, thrombocytopenia and risk of infections (Crvenkova 2018).

Toxicities associated with radiation therapy include radiation pneumonitis, radiation pneumonopathy, and acute oesophagitis (Yavas and Yavas 2017). PCI-related acute side effects include fatigue, alopecia, headaches and low-grade nausea while long term toxicities include memory loss, intellectual impairment or even dementia, and seizures (Yavas and Yavas 2017).

## **II: 1.2 Biliary Tract Cancer**

### **Incidence**

Biliary tract cancers are a group of rare and highly aggressive gastrointestinal cancers with wide geographical diversity (Turkes et al 2019). Biliary tract cancer is comprised of three primary subtypes: GBC, ampullary cancer, and cholangiocarcinomas (IHCC and extrahepatic cholangiocarcinoma [both perihilar and distal]) (Bridgewater et al 2016, Valle et al 2017, Oneda et al 2020).

Globally the incidence of BTC is low, accounting for approximately 3% of all adult cancers (Bridgewater et al 2016); however, incidence varies dependent on geographic region. The incidence rate of cholangiocarcinoma in Western countries is < 3 per 100000 person-years annually, whereas in Southern China and Northern Thailand, it can be up to 40 times higher. The incidence rate of GBC is uniform for most of the Western world, whereas disease clusters are found in India, Japan, and South America (SEER Program [Data Period 2008 to 2018], Valle et al 2021).

Age-standardised incidence rates, combining all main subtypes of BTC, based upon an analysis of data obtained from the IARC, are reported in [Table II-6](#). Incidence rates are shown to vary widely, ranging from 14.35 in Chile, to 1.25 in Vietnam. Countries in the Asia-Pacific region and South America have overall higher incidence rates per 100000 person-years (Asia-Pacific: 1.25 to 10.37, and South America: 3.07 to 14.35) compared with European and North American countries (Europe: 2.34 to 4.16, and North America: 2.67 and 2.70) ([Wang et al 2020a](#)).

**Table II-6 Incidence Rates Reported As Age-Standardised Rates per 100000 person-years by Country between 2008 to 2012**

Country	Incidence Rate	Country	Incidence Rate
Australia	2.76	Italy	4.16
China	3.87	Poland	3.38
Hong Kong	3.47	Spain	3.42
India	2.73	Switzerland	3.04
Japan	6.93	Turkey	2.5
Republic of Korea	10.37	UK	2.29
Thailand	4.72	Argentina	4.38
Vietnam	1.25	Brazil	3.07
Bulgaria	2.35	Chile	14.35
France	3.14	Canada	2.71
Germany	3.29	USA	2.67

Source: [Wang et al 2020a](#)

### **Prevalence**

The global prevalence of BTC has risen by a factor of 22%, with 150000 patients being diagnosed with BTC in 2015 ([GBD 2016](#)).

Furthermore, the 10-year prevalence of BTC in the US in 2015 was 10.8 per 100000 patients, with Hispanic and Asian/Pacific Islander groups reporting a higher 10-year prevalence of BTC (16.6 and 13.8, respectively) than the other ethnic groups ([Wang et al 2020b](#)).

### **Demographics of the population in the authorised indication (age, gender, racial and/or ethnic origin) and risk factors for the disease**

Analysis of data from the US NPCR and SEER databases between 2001 and 2015 indicated that age-standardised rates for BTC per 100000 person-years in the US was slightly higher in males versus females (5.31 versus 4.85, respectively), although females had a higher incidence of GBC than males (1.92 versus 1.14, respectively) ([Wang et al 2020b](#)).

In Europe, most biliary tumours occur sporadically after the age of 50, with a slight predominance of male patients ([Vogel et al 2021](#)).

In a published analysis of data from the US NPCR and SEER databases from 2006 to 2015, Hispanic Americans have a higher rate of BTC compared to non-Hispanic Americans. In addition, Blacks have a higher rate of BTC compared to Whites. Furthermore, these same data indicate that older age is a risk factor for BTC too ([Centers for Disease Control and Prevention 2018](#)).

Overall, the strongest risk factors for BTC are associated with chronic inflammation within the biliary system ([Marcano-Bonilla et al 2016](#)), however, there are differences in risk factors between the BTC subtypes. For example, risk factors for GBC include gallstones and gallbladder polyps. Risk factors for IHCC include, but are not limited to, primary sclerosing cholangitis, Caroli's disease, hepatolithiasis, cirrhosis, liver fluke infection, diabetes, hepatitis B and hepatitis C infections ([Bridgewater et al 2016](#), [Valle et al 2021](#)). Additionally, the geographical variation in incidence may reflect exposure to different risk factors. For example, the incidence of cholangiocarcinoma in Thailand reflects the impact of chronic infection with liver fluke. In the West, cholangiocarcinoma is associated with chronic inflammation of the biliary tree and hepatic parenchyma ([Bridgewater et al 2016](#)).

### **The main existing treatment options**

In patients who are diagnosed early (estimated to be less than 35% of patients globally, and approximately 10% of patients in the US), surgical resection is the only potentially curative treatment option ([Ghidini et al 2019](#), [Vogel et al 2021](#), [Marcano-Bonilla et al 2016](#)). However, over 75% of BTC patients present at a late unresectable stage; therefore, most patients are eligible for first-line systemic therapy ([Lamarca et al 2014](#), [Takahashi et al 2013](#)).

Gemcitabine plus cisplatin is recommended by global clinical practice guidelines including NCCN, ESMO, and Japanese guidelines ([Nagino et al 2021 \[Japanese BTC Treatment Guidelines 2019\]](#), [NCCN 2021a](#), [Valle et al 2016](#)). Other chemotherapy regimens are also actively used, and some are recommended by practice guidelines (eg, gemcitabine + S1 or gemcitabine/cisplatin + S1 in Japanese guidelines and multiple gemcitabine combination and platinum combinations in the NCCN guidelines) and have evidence to support their use in first-line advanced BTC ([Nagino et al 2021 \[Japanese BTC Treatment Guidelines 2019\]](#), [NCCN 2021a](#), [Sasaki et al 2021](#)).

Following first-line chemotherapy, patients usually experience disease progression, and a variety of regimens may be required to provide customised care for each patient's needs.

Additional targeted treatment options with tumour agnostic indications include pembrolizumab, and entrectinib and larotrectinib; however, these therapies are limited to those who progressed following prior treatment and/or who have no satisfactory alternative treatment options ([NCCN 2021c](#)).

### **Natural history of the indicated condition in the untreated population, including mortality and morbidity**

Biliary tract cancer is often difficult to diagnose due to its anatomical location and the non-specificity of symptoms. Consequently, approximately 75% of patients have locally advanced or metastatic disease at the time of diagnosis (Turkes et al 2019, Vogel et al 2021), at which time BTC has historically been associated with poor HRQoL (Heffernan et al 2002). Published qualitative research involving direct patient input, has identified significant symptomatic, functional, and HRQoL burden experienced by patients with advanced BTC (Butt et al 2012, Darwisch et al 2013, Elberg Densgø et al 2017).

In patients diagnosed at an early stage and eligible for curative resection surgery, the relapse rate is high, with approximately 50% to 70% of patients with BTC who undergo resection surgery developing recurrence (Elberg Densgø et al 2017, Ghidini et al 2019, Jung et al 2012, Tsilimigras et al 2020). For patients presenting at a late unresectable stage, treatment options are mainly palliative; advanced BTC patients who receive SoC chemotherapy have an extremely poor prognosis (median OS of approximately 1 year, and a 5-year overall survival of 7% to 20%) (Banales et al 2020, Eckel and Schmid 2007, Valle et al 2017, Yachimski and Pratt 2008).

For patients who are ineligible for treatment, approximately half die within 3 to 4 months of presentation from the indirect effects of local tumour progression, bile duct obstruction, liver failure, or sepsis from cholangitis and abscesses (Patel 2011).

### **Important comorbidities**

Data describing comorbidities for patients with BTC is limited. Common comorbidities for BTC patients are hypertension, diabetes mellitus, chronic obstructive pulmonary disease, coronary heart disease, and cerebrovascular disease (Fernández-Ruiz et al 2009, Takahara et al 2020).

## **II: 1.3 Hepatocellular Carcinoma**

### **Incidence**

Primary liver cancer is a major global health problem accounting for approximately 906000 new cases per year globally (American Cancer Society 2021). In Europe, approximately 87000 new cases a year are reported (WHO 2020), whereas the US reports approximately 42000 new cases a year (American Cancer Society 2021). As of 2020, liver cancer was the seventh most common cancer worldwide (Sung et al 2021).

Hepatocellular carcinoma is the most common histologic type of primary liver cancer, accounting for around 90% of these malignancies (EASL 2018). The incidence of HCC varies globally due to the difference in the prevalence of risk factors across geographic regions

(Sung et al 2021). The highest incidence rates are seen in East Asia and Sub-Saharan Africa, while lower rates are seen in Europe and North America (WHO 2019).

Table II-7 presents an estimated incidence of liver cancer and HCC worldwide, by region and gender.

**Table II-7 Estimated Number of Incidence Cases of Liver Cancer and HCC, by Gender and Region, 2018**

Population	Liver Cancer				HCC			
	Incident cases		Crude incidence rate (per 100000)		Incident cases		Crude incidence rate (per 100000)	
	Male	Female	Male	Female	Male	Female	Male	Female
World	596574	244506	15.5	6.5	536917	220055	14.0	5.9
Asia	443744	165852	19.1	7.5	399370	149267	17.2	6.8
Europe	55825	26641	15.5	6.9	50243	23977	14.0	6.2
Africa	43530	21249	6.8	3.3	39177	19124	6.1	3.0
North America	29900	11951	16.6	6.5	26910	10756	14.9	5.9
Latin America and the Caribbean	20784	17616	6.5	5.3	18706	15854	5.9	4.8
Oceania	2791	1197	13.5	5.8	2512	1077	12.2	5.2

Although IARC estimates for HCC prevalence are not readily available, they are calculated based on evidence from the literature that indicates HCC accounts for approximately 90% of all cases of primary liver cancer (Llovet et al 2016).  
Source: Bray et al 2018.

### **Prevalence**

Using 2017 data from the GBD project, the estimated crude 1-year prevalence rate of liver cancer was 3.99 per 100000 individuals in Europe (Institute for Health Metrics and Evaluation 2017).

A north-south gradient was seen in the estimated age-standardised prevalence rate for HCC within Europe. According to the GBD 2016 project, the prevalence rate in Italy was greater than 12 per 100000, while the rates were slightly lower for Austria, Germany, Luxembourg, and Switzerland (range: 6 to 11.99 per 100000). In the same year, countries such as Poland and Hungary had prevalence rates of HCC below 5 per 100000 (Institute for Health Metrics and Evaluation 2016).

Table II-8 presents the estimated 5-year prevalence of liver cancer and HCC worldwide and by region extracted from IARC.



**Table II-8 Estimated 5-Year Prevalence of HCC Worldwide and by Region, 2018**

Region	Liver Cancer		HCC	
	Five-year prevalence <sup>a</sup>	Proportion/100000 <sup>b</sup>	Five-year prevalence	Proportion/100000
Worldwide	675210	8.8	607689	7.9
Asia	494783	10.9	445305	9.8
Europe	58477	7.9	52629	7.1
Africa	56736	4.4	51062	4.0
North America	34107	9.4	30696	8.5
Latin America and the Caribbean	27795	4.3	25016	3.9
Oceania	3312	8.0	2981	7.2

<sup>a</sup> 5-year prevalence: defined as sum of region-specific prevalence cases over 5 years.

<sup>b</sup> Proportion/100000: defined as proportion of population per 100000 persons.

Although IARC estimates for HCC prevalence are not readily available, they are calculated based on evidence from the literature that indicates HCC accounts for approximately 90% of all cases of primary liver cancer (Llovet et al 2016).

Source: Bray et al 2018.

### **Demographics of the population in the authorised indication (age, gender, racial and/or ethnic origin) and risk factors for the disease**

The incidence of HCC increases progressively with advancing age in all populations, reaching a peak at 70 years (El Serag 2012, White et al 2017). While HCC is more common in men than women (2- to 3-fold higher), it is believed this is most likely due to differences in the behaviours associated with relevant risk factors rather than underlying risk (Llovet et al 2016, Sung et al 2021).

Cirrhosis and chronic liver disease are the most important risk factors for HCC (Balogh et al 2016, Asrani et al 2019, Janevska et al 2015). Viral hepatitis infections, alcohol abuse, and metabolic diseases including obesity and diabetes mellitus are all conditions that may result in cirrhosis and the chronic liver damage that is associated with increased risk for HCC (Balogh et al 2016, Asrani et al 2019, Massarweh and El-Serag 2017, Reeves et al 2016).

Globally, chronic infections with hepatitis B or C virus are the most commonly occurring risk factors for HCC (Caldwell and Park 2009). Approximately 80% of HCC cases worldwide can be attributed to either hepatitis B or C virus (Caldwell and Park 2009). Other HCC risk factors include exposure to aflatoxin (Janevska et al 2015), tobacco use, and certain genetic conditions including Wilson disease (Balogh et al 2016).

### **The main existing treatment options**

The ESMO and the European Association for the Study of the Liver 2018 guidelines recommend systemic therapies for the management of unresectable HCC. Since 2020, the NCCN, ESMO, and Japanese Society of Hepatology guidelines have recommended atezolizumab (a PD-L1 inhibitor) in combination with bevacizumab (an angiogenesis inhibitor



targeting vascular endothelial growth factor A) as the preferred option to treat first-line HCC (NCCN 2021a, JSH 2021, Vogel and Martinelli 2021 [ie, ESMO Guidelines 2021]).

Prior to 2020, sorafenib (an oral tyrosine kinase inhibitor targeting multiple kinases) was considered the standard of care for advanced HCC in the first-line setting since its approval in 2007 (EASL 2018, Vogel et al 2018). Lenvatinib (a multiple kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3 and fibroblast growth factor receptor-1, -2, -3, and -4) is also approved as first-line treatment for advanced HCC in patients without main portal vein invasion and a Performance Status of 0 to 1.

Selective internal radiation therapy may be considered as an alternative therapy, following multidisciplinary board discussion, in exceptional circumstances and in a subset of patients for whom systemic therapy is not possible (EASL 2018, Vogel et al 2018).

**Natural history of the indicated condition in the untreated population, including mortality and morbidity**

The 5-year survival rate for HCC is less than 20% (Sarveazad et al 2019, Villanueva 2019), with a median survival following diagnosis ranging from 6 to 20 months (McGlynn et al 2015).

Hepatocellular carcinoma is often associated with non-specific complaints. Patients typically manifest symptoms related to underlying cirrhosis, a condition present in 80% to 90% of patients with HCC (Tinkle and Haas-Kogan 2012). Rarely, patients may present with acute onset of severe symptoms (Rossetto et al 2010). Hepatocellular carcinoma is also associated with a number of paraneoplastic syndromes. Extrahepatic spread at presentation is relatively uncommon, ranging between 10% and 30%. The most common sites of metastasis include lung, adrenal gland, regional lymph node and bone (El-Serag and Rudolph 2007, Tinkle and Haas-Kogan 2012).

Hepatocellular carcinoma carries a substantial mortality and morbidity burden (Tinkle and Haas-Kogan 2012), with HCC mortality rates increasing over recent decades in most countries. As of 2020, liver cancer was the third most common cause of cancer-related death (Sung et al 2021). Global variation in mortality estimates for liver cancer, of which approximately 90% of cases are HCC (Mak et al 2018) can be assessed through data extracted from the GLOBOCAN series (Table II-9).

**Table II-9 Estimated Number of Deaths due to Liver Cancer, by Gender and Region, 2018**

Population	Number of Deaths		Crude Mortality Rate (per 100000)	
	Male	Female	Male	Female
World	548375	233256	14.2	6.2

**Table II-9 Estimated Number of Deaths due to Liver Cancer, by Gender and Region, 2018**

Population	Number of Deaths		Crude Mortality Rate (per 100000)	
	Male	Female	Male	Female
Asia	410223	156046	17.6	7
Europe	50365	27010	14	7
Africa	42786	20776	6.7	3.2
North America	22889	11450	12.7	6.2
Latin America and the Caribbean	19650	16786	6.1	5.1
Oceania	2462	1188	11.9	5.8

Source: [Bray et al 2018](#).

Untreated patients with advanced HCC, those who have macrovascular invasion or extrahepatic spread (lymph node involvement or metastases), have a median survival of 6 months ([Llovet et al 2016](#)) and a 25% survival at 1-year ([Cabibbo et al 2010](#)). Patients with end-stage disease have a median survival of 3 to 4 months ([Llovet et al 1999](#)) and an 11% survival at 1-year ([Cabibbo et al 2010](#)).

### **Important comorbidities**

The most common liver-related comorbidities in patients with advanced HCC include cirrhosis, hepatitis B, hepatitis C, non-alcoholic steatohepatitis and/or non-alcoholic fatty liver disease, alcohol dependence, and portal vein thromboembolism ([Bonafede et al 2020](#), [Mallick et al 2013](#)).

In general, elderly patients with advanced HCC also have high incidence of comorbidities such as cardiovascular disease, diabetes mellitus, and chronic renal disease ([Nishikawa et al 2013](#)). Hypertension, diabetes, anxiety, cardiovascular disease, chronic obstructive pulmonary disease, depression, osteoarthritis, osteoporosis, and chronic kidney disease are also reported among patients with advanced HCC ([Bonafede et al 2020](#), [Lee et al 2018b](#), [Arora et al 2016](#)).

## **II: 1.4 Endometrial Cancer**

### **Incidence**

Endometrial cancer is the sixth most common cancer among women, with 417367 new cases being recorded worldwide in 2020, and an age-standardised incidence rate of 8.7 per 100000 women ([Sung et al 2021](#)). The highest age-standardised incidence rates of endometrial cancer have been recorded in Europe, North America, Australia/New Zealand, and Polynesia/Micronesia, while the lowest age-standardised incidence rates of endometrial cancer have been recorded in most regions of Africa and South Central Asia ([Sung et al 2021](#)).

In Europe, the age-standardised incidence rate per 100000 women for the year 2020 was 16.4 for Northern Europe, 14.2 for Southern Europe, 12.9 for Western Europe, and 20.2 for Eastern Europe ([Sung et al 2021](#)).

### **Prevalence**

Endometrial cancer is the most prevalent gynaecologic cancer in high income countries ([Ferlay et al 2015](#)). In 2020, the 5-year prevalence rate for endometrial cancer in Europe was 124.74 per 100000 women ([International Agency for Research on Cancer 2021](#)). In 2023, endometrial cancer was the fourth most prevalent cancer among women in the US (7% of cancer cases) ([Siegel et al 2023](#)).

### **Demographics of the population in the proposed indication – age, gender, racial and/or ethnic origin and risk factors for the disease**

Incidence of endometrial cancer increases with age. Across Europe, the incidence of endometrial cancer is at least 10 times greater among post-menopausal women compared to pre-menopausal women ([Bray et al 2005](#)).

Racial differences in endometrial cancer diagnosis have also been observed. For example, a large, prospective, cohort study conducted in the US demonstrated that the risk of endometrial cancer in women of White ethnicity far exceeded that of African Americans, Native Hawaiians, Japanese Americans, and Latinas; however, African Americans had the highest risk of developing advanced cancer, and African Americans and Latinas had the highest risk of developing tumours with aggressive histology ([Setiawan et al 2007](#)). Furthermore, a retrospective cohort study of women living in the UK found that women of South Asian ethnicity were diagnosed at a significantly younger age (mean age: 60.3 years) than women of White ethnicity (mean age: 66.9 years) ([Mohammed et al 2021](#)).

Results from meta-analyses have found highly suggestive evidence that BMI (per 5 kg/m<sup>2</sup>), height (per 10 cm), waist circumference (per 10 cm), weight gain (per 5 kg), type I and type II diabetes mellitus, sedentary behaviour, hypertension, and nulliparity are associated with increased risk of endometrial cancer ([Raglan et al 2019](#)).

Additionally, there is suggestive evidence that coffee intake (per one cup/day), physical activity, age at menarche (per 2-year delay), age at last birth (per 5-year increment), metformin use, oral contraceptive use, and smoking are associated with decreased risk of endometrial cancer ([Raglan et al 2019](#)).

### **The main existing treatment options**

The current standard of care for the first-line treatment for patients with advanced or recurrent endometrial cancer comprises platinum-based chemotherapy, with the combination of carboplatin and paclitaxel the preferred regimen ([NCCN 2023](#), [Oaknin et al 2022](#)).

For patients who progress following prior platinum-based chemotherapy, pembrolizumab (as monotherapy or in combination with lenvatinib) and dostarlimab (as monotherapy) are approved and recommended in NCCN and ESMO guidelines as second-line treatment for patients who have progressed following prior treatment and who have no satisfactory alternative treatment options, with the choice of treatment guided by a patient's deficient mismatch repair or proficient mismatch repair status ([NCCN 2023](#), [Oaknin et al 2022](#)).

### **Natural history of the indicated condition in the untreated population, including mortality and morbidity**

Globally, the age-standardised mortality rate for cancer of the corpus uteri is 1.8 per 100000, with the highest rates in Eastern Europe (3.7 per 100,000), Micronesia/Polynesia (3.5 per 100000), and Northern America (3.0 per 100000) ([Sung et al 2021](#)). A total of 97370 deaths worldwide were recorded in 2020 ([Sung et al 2021](#)).

Endometrial cancer often presents as post-menopausal bleeding with a median age at diagnosis of 61 years ([Crosbie et al 2022](#)). The majority of patients are diagnosed at an early stage (Stage I or II) and these patients have a better prognosis with 5-year survival rates ranging from 74% to 91% ([Creasman et al 2006](#)). For patients diagnosed at a later stage or with advanced endometrial cancer the 5-year survival rates range from 50% to 66% for Stage III and 20% to 26% for Stage IV disease ([Creasman et al 2006](#)). The poor survival rate for advanced endometrial cancer is due, in part, to the limited treatment options available after first-line chemotherapy ([Halla 2022](#)).

### **Important co-morbidities**

In a retrospective study of 594 endometrial cancer or endometrial lesions cases in Romania, the most common co-morbidities were hypertension (62.28%), obesity (35.01%), and diabetes (22.89%) ([Furau et al 2021](#)). Endometrial cancer has also been associated with co-morbid hypertension in meta-analyses ([Connaughton and Dabagh 2022](#)) and database studies ([Nicholas et al 2014](#)), and compared to patients without endometrial cancer, patients with a diagnosis of endometrial cancer had a higher prevalence of cardiovascular disease at cancer index date and an increased risk for developing cardiovascular disease including ischaemic heart diseases, pulmonary heart disease, and diseases of the veins and lymphatics after endometrial cancer diagnosis ([Anderson et al 2022](#)).

Additionally, evidence suggests that metabolic syndrome may be a co-morbidity in endometrial cancer. In a systematic literature review, the prevalence of metabolic syndrome in endometrial cancer patients compared to individuals without endometrial cancer varied based on metabolic syndrome definition, ranging from 6% versus 2% (International Diabetes Federation definition) to 62% versus 38% (Harmonised metabolic syndrome guidelines) ([Adambekov et al 2019](#)).

## II: 2 MODULE SII: NON-CLINICAL PART OF THE SAFETY SPECIFICATION

### II: 2.1 Summary of Key Safety Findings from Non-Clinical Data

Key safety findings from the non-clinical toxicology and safety pharmacology studies with potential relevance to human usage are described in [Table II-10](#).

**Table II-10 IMFINZI: Key Findings from Non-clinical Data**

<b>Toxicity</b>
<b>Key issues identified from acute or repeat-dose toxicity studies</b>
Administration of IMFINZI to cynomolgus monkeys was not associated with any treatment-related adverse effects considered relevant to humans. The only adverse findings in the repeat-dose toxicity studies were consistent with antidrug antibody-associated morbidity and mortality. Similar observations have been made in cynomolgus monkeys administered human mAbs unrelated to IMFINZI, and it is generally recognised that immunogenicity of human mAbs in non-clinical species and consequent adverse events are not predictive for humans. In the pivotal Good Laboratory Practice, 13-week, repeat-dose toxicity study in cynomolgus monkeys, treatment with IMFINZI was not associated with any adverse effects. No safety concerns relevant to human usage have been identified.
<b>Reproductive/development toxicity</b>
In the 3-month iv repeat-dose toxicity study in sexually mature cynomolgus monkeys, no treatment-related effects were observed on the male or female reproductive organs, the regulatory accepted surrogate endpoint for fertility in nonhuman primates. In an ePPND study, iv administration of IMFINZI from confirmation of pregnancy (gestation day 20) until parturition was associated with an apparent increase in mid- and late-stage pregnancy losses, stillbirths or infants found dead, and total pregnancy and infant losses compared to a concurrent control, without a clear trend in dose relationship. Pregnancy outcomes in the IMFINZI -treated groups were within the normal range when compared to historical control. Considering the findings in the ePPND study and scientific literature data indicating a role for PD-1/PD-L1 interactions on the maternal-foetal interface, with antibody-mediated PD-L1 blockade resulting in an increase in foetal resorption in mice ( <a href="#">D'Addio et al 2011</a> , <a href="#">Guleria et al 2005</a> , <a href="#">Taglauer et al 2009</a> ), appropriate labelling and risk management procedures for women of childbearing potential are warranted.
<b>Genotoxicity</b>
In accordance ICH S6(R1) guidance, genotoxicity testing has not been conducted with IMFINZI and is not planned. Genotoxicity is not applicable to biotechnology-derived large protein products, as they are not expected to cross the nuclear or mitochondrial membrane and interact directly with DNA or other chromosomal material. No safety concerns relevant to human usage have been identified.
<b>Carcinogenicity</b>
In accordance with ICH S6(R1) and ICH S9 guidance, carcinogenicity studies have not been conducted with IMFINZI and are not planned given the characteristics of the product and the intended clinical use in patients with advanced cancer. No safety concerns relevant to human usage have been identified.
<b>Safety pharmacology</b>
In accordance with ICH S6(R1) and ICH S7A, no stand-alone safety pharmacology studies were conducted with IMFINZI, and safety pharmacology endpoints (including neurological [assessed by clinical observations], cardiovascular [electrocardiogram and blood pressure] parameters, and respiration rate) were included in repeat-dose toxicity studies. No IMFINZI-related effects on any of the parameters evaluated were observed.

## II: 3 MODULE III: CLINICAL TRIAL EXPOSURE

IMFINZI is indicated for use as monotherapy and in combination with other anticancer agents. The key features of all studies included in this RMP are summarised in [Table II-11](#).

In order to evaluate the safety and tolerability of IMFINZI monotherapy, data from a number of key studies have been pooled to create a pan-tumour dataset. This population (N = 3006) consists of patients who have received at least 1 dose of IMFINZI monotherapy given at a dose of either 10 mg/kg Q2W iv or 20 mg/kg Q4W iv for any line of therapy (across tumour types). A summary of exposure data pertaining to the IMFINZI monotherapy pool is provided in Section [II: 3.6](#).

Data from IMFINZI in combination with other anticancer agents (and from monotherapy treatment arms of later studies in the IMFINZI clinical development program) are not included in the pan-tumour monotherapy pool, and are described separately by treatment regimen (where relevant) in the following sections: Section [II: 3.1](#) (IMFINZI in combination with SoC chemotherapy [paclitaxel and carboplatin] followed by IMFINZI with or without olaparib as maintenance treatment in patients with endometrial cancer), Section [II: 3.2](#) (IMFINZI in combination with chemotherapy [gemcitabine and cisplatin] in patients with BTC), Section [II: 3.3](#) (IMFINZI in combination with tremelimumab [plus SoC chemotherapy] in patients with metastatic NSCLC), Section [II: 3.4](#) (IMFINZI as monotherapy and in combination with tremelimumab in patients with advanced or unresectable HCC), and Section [II: 3.5](#) (IMFINZI in combination with etoposide plus platinum-based chemotherapy [carboplatin or cisplatin] in patients with ES-SCLC).

**Table II-11 Summary of Studies Included in the RMP**

Study name (number) Data cut-off	Study design	Treatment arms	Patient population
<b>CASPIAN</b> (D419QC00001 [NCT03043872]) 26 April 2019	Phase III Randomised, open-label, comparative, multicentre	<ul style="list-style-type: none"> <li>• D + EP</li> <li>• D + T + EP</li> <li>• EP</li> </ul>	Patients with ES-SCLC
<b>POSEIDON</b> (D419MC00004 [NCT03164616]) 12 Mar 2021	Phase III Randomised, open-label, comparative, multicentre	<ul style="list-style-type: none"> <li>• D</li> <li>• D + T</li> <li>• D + T + SoC</li> </ul>	Patients with metastatic (Stage IV) NSCLC, with tumours that lack activating EGFR mutations and ALK fusions. Patients must have had no prior chemotherapy or any other systemic therapy for metastatic NSCLC.

**Table II-11 Summary of Studies Included in the RMP**

<b>Study name (number) Data cut-off</b>	<b>Study design</b>	<b>Treatment arms</b>	<b>Patient population</b>
<b>HIMALAYA</b> (D419CC00002 [NCT03298451]) 27 Aug 2021	Phase III Randomised, open-label, multicentre	<ul style="list-style-type: none"> <li>• D</li> <li>• D + T75</li> <li>• D + T300</li> <li>• Sorafenib</li> </ul>	Patients with unresectable HCC not eligible for locoregional therapy who have not received prior systemic therapy for HCC (first-line setting)
<b>Study 22</b> (D4190C00022 [NCT02519348]) 06 Nov 2020	Phase II Randomised, open-label, multicentre	<ul style="list-style-type: none"> <li>• D</li> <li>• D + T75</li> <li>• D + T300</li> <li>• T</li> </ul>	Patients with unresectable HCC who were immunotherapy-naïve and had either progressed on, were intolerant to, or refused treatment with sorafenib or other approved VEGFR
<b>TOPAZ-1</b> (D933AC00001 [NCT03875235]) 11 Aug 2021	Phase III Randomised, double-blind, placebo-controlled, multicentre	<ul style="list-style-type: none"> <li>• D + Gem/Cis</li> <li>• Placebo + Gem/Cis</li> </ul>	Patients with previously untreated, unresectable locally advanced or metastatic BTC
<b>DUO-E</b> (D9311C00001 [NCT04269200]) 12 April 2023	Phase III Randomised, double-blind, placebo-controlled, multicentre	<ul style="list-style-type: none"> <li>• SoC + D</li> <li>• SoC + D + O</li> <li>• SoC</li> </ul>	Patients with advanced or recurrent endometrial cancer who were eligible for treatment with first-line SoC chemotherapy (carboplatin and paclitaxel)
<b>Studies included in the IMFINZI monotherapy pan-tumour pool</b>			
<b>Study 1108</b> (CD-ON- MEDI4736-1108 [NCT01693562]) 16 Oct 2017	Phase I/IIb first-time-in-human, open-label, 3 + 3 dose-escalation, dose-expansion	<ul style="list-style-type: none"> <li>• D (NSCLC)</li> <li>• D (UC)</li> </ul>	Patients with advanced solid tumours, including NSCLC, that are refractory to standard therapy and for which no standard therapy exists
<b>Japan 002</b> (D4190C00002 [NCT01938612]) 31 Mar 2018	Phase I Open-label, multicentre	<ul style="list-style-type: none"> <li>• D</li> <li>• D + T</li> </ul>	Patients with advanced solid tumours, including NSCLC, that are refractory to standard therapy and for which no standard therapy exists
<b>ATLANTIC</b> (D4191C00003 [NCT02087423]) 03 Jun 2016	Phase II Non-comparative, open-label, multicentre, international	<ul style="list-style-type: none"> <li>• D</li> </ul>	Patients with locally advanced or metastatic NSCLC (Stage IIIB-IV) who have received at least 2 prior systemic treatment regimens
<b>PACIFIC</b> (D4191C00001 [NCT02125461]) 22 Mar 2018	Phase III Randomised, double-blind, placebo-controlled, multicentre, international	<ul style="list-style-type: none"> <li>• D</li> <li>• Placebo</li> </ul>	Patients with locally advanced, unresectable, Stage III NSCLC who have not progressed after definitive platinum-based concurrent chemoradiation



**Table II-11 Summary of Studies Included in the RMP**

<b>Study name (number) Data cut-off</b>	<b>Study design</b>	<b>Treatment arms</b>	<b>Patient population</b>
<b>ARCTIC</b> (D4191C00004 [NCT02352948]) 09 Feb 2018	Phase III Randomised, open-label, multicentre, international	<u>Substudy A:</u> <ul style="list-style-type: none"> <li>• D</li> <li>• Chemotherapy</li> </ul> <u>Substudy B:</u> <ul style="list-style-type: none"> <li>• D</li> <li>• Chemotherapy</li> <li>• T</li> <li>• D + T</li> </ul>	Patients with locally advanced or metastatic NSCLC (Stage IIIB-IV) who received at least 2 prior systemic treatments and do not have EGFR or ALK target mutations
<b>MYSTIC</b> (D419AC00001 [NCT02453282]) 04 Oct 2018	Phase III Randomised, open-label, multicentre, international	<ul style="list-style-type: none"> <li>• D</li> <li>• D + T</li> <li>• Chemotherapy</li> </ul>	Patients with Stage IV NSCLC who have not received prior chemotherapy or other systemic therapy and who do not have EGFR or ALK target mutations
<b>HAWK</b> (D4193C00001 [NCT02207530]) 05 Oct 2018	Phase II Single-arm, multicentre, international	<ul style="list-style-type: none"> <li>• D</li> </ul>	Patients with recurrent or metastatic HNSCC not amenable to therapy with curative intent
<b>CONDOR</b> (D4193C00003 [NCT02319044]) 27 Aug 2018	Phase II Randomised, open-label, multicentre, international	<ul style="list-style-type: none"> <li>• D</li> <li>• T</li> <li>• D + T</li> </ul>	Patients with recurrent or metastatic HNSCC not amenable to therapy with curative intent
<b>EAGLE</b> (D4193C00002 [NCT02369874]) 10 Sep 2018	Phase III Randomised, open-label, multicentre, international	<ul style="list-style-type: none"> <li>• D</li> <li>• T</li> </ul>	Patients with recurrent or metastatic HNSCC not amenable to therapy with curative intent

### **II: 3.1 Exposure to IMFINZI + SoC Chemotherapy Followed by IMFINZI ± Olaparib as Maintenance Treatment for Endometrial Cancer**

The pivotal safety dataset in support of the use of IMFINZI in combination with SoC chemotherapy (carboplatin and paclitaxel), followed by maintenance with IMFINZI as monotherapy or in combination with olaparib in patients with endometrial cancer was derived from the SoC + D and SoC + D + O arms of the DUO-E study (see [Table II-11](#) for details). Patients were to receive SoC chemotherapy and IMFINZI 1120 mg via iv infusion Q3W for 4 to 6 cycles during the chemotherapy phase. Patients who achieved and maintained disease control were subsequently to receive IMFINZI 1500 mg Q4W in conjunction with olaparib or placebo (2 × 150 mg tablets twice daily) in the maintenance phase.



Exposure to IMFINZI in the SoC + D and SoC + D + O arms of the DUO-E study by weeks, age group, and race is presented in [Table II-12](#), [Table II-13](#), and [Table II-14](#), respectively. Of note, all patients were female.

**Table II-12 Duration of Exposure to IMFINZI (SoC + D and SoC + D + O Arms; DUO-E Study [Overall Period])**

Duration of exposure (weeks)	SoC + D (N = 235)		SoC + D + O (N = 238)	
	n	Patient-years exposure	n	Patient-years exposure
≥ 0	235	224.7	238	265.2
≥ 6	225	224.2	233	265.0
≥ 12	211	222.2	218	262.3
≥ 24	182	212.2	198	255.6
≥ 32	152	195.3	178	244.4
≥ 40	128	179.0	162	233.4
≥ 48	103	158.2	135	210.4
≥ 52	96	151.5	129	204.6
≥ 76	51	96.4	70	132.6
≥ 104	18	40.3	21	48.3
≥ 132	3	7.8	6	15.7

Total treatment duration = (last dose date + X days or death date or DCO whichever occurs earlier - first dose date + 1)/7, where X is defined as the planned frequency in dosing (in days) - 1. For Q4W, X = 27.

Overall period = Chemotherapy phase + Maintenance phase.

**Table II-13 Exposure to IMFINZI by Age Group (SoC + D and SoC + D + O Arms; DUO-E Study [Overall Period])**

Age group (years)	SoC + D (N = 235)		SoC + D + O (N = 238)	
	n	Patient-years exposure	n	Patient-years exposure
< 65	120	118.8	134	151.9
≥ 65 to < 75	87	80.4	85	96.2
≥ 75	28	25.5	19	17.1
<b>Total</b>	<b>235</b>	<b>224.7</b>	<b>238</b>	<b>265.2</b>

Patient-years exposure = Total treatment duration (years) summed across all patients within a group. Where treatment duration (years) = (last dose date + X days or death date or DCO whichever occurs earlier - first dose date + 1) / 365.25. X is defined as the planned frequency in dosing (in days) - 1. For Q3W, X = 20. For Q4W, X = 27.

Overall period = Chemotherapy phase + Maintenance phase.

**Table II-14 Exposure to IMFINZI by Race (SoC + D and SoC + D + O Arms; DUO-E Study [Overall Period])**

Race	SoC + D (N = 235)		SoC + D + O (N = 238)	
	n	Patient-years exposure	n	Patient-years exposure
White	134	135.5	133	147.0
Asian	71	64.3	69	80.6
Black or African American	11	7.6	14	15.5
Other	14	12.5	19	18.0
Not reported	5	4.8	3	4.1
<b>Total</b>	<b>235</b>	<b>224.7</b>	<b>238</b>	<b>265.2</b>

Patient-years exposure = Total treatment duration (years) summed across all patients within a group. Where treatment duration (years) = (last dose date + X days or death date or DCO whichever occurs earlier - first dose date + 1) / 365.25. X is defined as the planned frequency in dosing (in days) - 1. For Q3W, X = 20. For Q4W, X = 27.  
Overall period = Chemotherapy phase + Maintenance phase.

### II: 3.2 Exposure to IMFINZI + SoC Chemotherapy for BTC

The pivotal safety dataset in support of the use of IMFINZI in combination with SoC chemotherapy (gemcitabine and cisplatin) in patients with previously untreated, unresectable locally advanced or metastatic BTC was derived from the D + Gem/Cis arm of the TOPAZ-1 study (see [Table II-11](#) for details), in which IMFINZI 1500 mg was administered in combination with cisplatin 25 mg/m<sup>2</sup> and gemcitabine 1000 mg/m<sup>2</sup> (each administered on Days 1 and 8; Q3W) via iv infusion (on Day 1; Q3W); starting on Cycle 1, for up to 8 cycles. After completing the chemotherapy treatment period, patients received IMFINZI 1500 mg monotherapy via iv infusion Q4W until clinical or radiological (per RECIST v1.1) disease progression or until unacceptable toxicity, withdrawal of consent, or any other discontinuation criteria were met. Patients who were clinically stable at initial disease progression could continue to receive study treatment at the discretion of the investigator and patient.

Exposure to IMFINZI in the D + Gem/Cis arm of the TOPAZ-1 study by weeks, age group and sex, and race is presented in [Table II-15](#), [Table II-16](#), and [Table II-17](#), respectively.

**Table II-15 Duration of Exposure to IMFINZI (D + Gem/Cis Arm; TOPAZ-1 Study) (N = 338)**

Duration of exposure (weeks)	n	Patient-years exposure
≥ 0	338	215.2
≥ 8	304	212.5
≥ 16	257	202.0
≥ 24	225	190.0
≥ 32	176	164.0
≥ 40	110	119.3

**Table II-15 Duration of Exposure to IMFINZI (D + Gem/Cis Arm; TOPAZ-1 Study) (N = 338)**

Duration of exposure (weeks)	n	Patient-years exposure
≥ 48	60	78.5
≥ 50	53	72.0
≥ 52	49	68.2
<b>Total</b>	<b>338</b>	<b>215.2</b>

Total exposure months = (min(last IMFINZI dose date where dose > 0 + [20 if last dose in period 1 or 27 if last dose in period 2], date of death, date of DCO) - first IMFINZI dose date + 1) / (365.25/12). Note: For each subject, weeks and years of exposure are derived from months of exposure.

**Table II-16 Exposure to IMFINZI by Age Group and Gender (D + Gem/Cis Arm; TOPAZ-1 Study) (N = 338)**

Age group (years)	Male		Female	
	n	Patient-years exposure	n	Patient-years exposure
< 65	94	60.5	86	55.2
≥ 65	75	45.2	83	54.3
<b>Total</b>	<b>169</b>	<b>105.7</b>	<b>169</b>	<b>109.6</b>

Total exposure months = (min (last IMFINZI dose date where dose > 0 + [20 if last dose in period 1 or 27 if last dose in period 2], date of death, date of DCO) - first IMFINZI dose date + 1) / (365.25/12). Note: For each subject, years of exposure is derived from months of exposure.

**Table II-17 Exposure to IMFINZI by Race (D + Gem/Cis Arm; TOPAZ-1 Study) (N = 338)**

Race	n	Patient-years exposure
Asian	184	123.1
White	129	77.0
Other	17	10.7
Black or African American	8	4.5
<b>Total</b>	<b>338</b>	<b>215.2</b>

Total exposure months = (min (last IMFINZI dose date where dose > 0 + [20 if last dose in period 1 or 27 if last dose in period 2], date of death, date of DCO) - first IMFINZI dose date + 1) / (365.25/12). Note: For each subject, years of exposure is derived from months of exposure.

### II: 3.3 Exposure to IMFINZI + Tremelimumab + SoC Chemotherapy for Metastatic NSCLC

The pivotal dataset in support of the use of IMFINZI in combination with tremelimumab and platinum-based chemotherapy (SoC) for the first-line treatment of metastatic NSCLC was derived from the D + T + SoC chemotherapy arm of the POSEIDON study (see [Table II-11](#) for details), in which IMFINZI 1500 mg plus tremelimumab 75 mg was administered via iv infusion concurrently with platinum-based doublet chemotherapy (either abraxane or gemcitabine or pemetrexed [dependent on NSCLC histology] plus cisplatin or carboplatin)

Q3W for 4 cycles (1 cycle = 3 weeks). Post-chemotherapy, IMFINZI monotherapy (plus pemetrexed maintenance treatment [unless contraindicated, based on investigator discretion] for participants with non-squamous tumours who had previously received chemotherapy with pemetrexed plus carboplatin/cisplatin) was continued Q4W until disease progression or unacceptable toxicity. In addition, 1 further dose of tremelimumab was administered alongside IMFINZI dose 6 at Week 16.

Exposure to IMFINZI and tremelimumab in the D + T75 + SoC arm of the POSEIDON study by weeks, age group and gender, and race is presented in [Table II-18](#), [Table II-19](#), and [Table II-20](#), respectively.

**Table II-18 Duration of exposure to IMFINZI and Tremelimumab (D + T75 + SoC Arm; POSEIDON Study) (N=330)**

Duration of exposure (weeks)	IMFINZI (N=330)		Tremelimumab (N=330)	
	n	Patient-years exposure	n	Patient-years exposure
≥0	330	308.8	330	112.4
≥8	280	304.6	280	108.3
≥16	250	298.1	228	96.3
≥24	198	278.2	38	20.6
≥32	153	254.1	7	4.8
≥40	125	234.7	0	0.0
≥48	107	219.6	0	0.0
≥50	100	213.1	0	0.0
≥52	97	210.2	0	0.0
<b>Total</b>	<b>330</b>	<b>308.8</b>	<b>330</b>	<b>112.4</b>

Total exposure = Minimum of (last infusion/dose date of the last cycle + 20 days (if last infusion/dose date was during combination)/last infusion/dose date of the last cycle + 27 days (if last infusion/dose date was in maintenance or tremelimumab retreatment), date of death, date of DCO) – first infusion/dose date of first cycle + 1.

**Table II-19 Exposure to IMFINZI and Tremelimumab by Age Group and Sex (D + T75 + SoC Arm; POSEIDON Study) (N=330)**

Age group (years)	IMFINZI (N=330)				Tremelimumab (N=330)			
	Male		Female		Male		Female	
	n	Patient-years exposure	n	Patient-years exposure	n	Patient-years exposure	n	Patient-years exposure
<65	151	145.6	36	36.0	151	51.6	36	12.4
≥65	113	101.8	30	25.5	113	38.1	30	10.3
<b>Total</b>	<b>264</b>	<b>247.4</b>	<b>66</b>	<b>61.4</b>	<b>264</b>	<b>89.7</b>	<b>66</b>	<b>22.7</b>

Total exposure = Minimum of (last infusion/dose date of the last cycle + 20 days (if last infusion/dose date was during combination)/last infusion/dose date of the last cycle + 27 days (if last infusion/dose date was in maintenance or tremelimumab retreatment), date of death, date of DCO) – first infusion/dose date of first cycle + 1.

**Table II-20 Exposure to IMFINZI and Tremelimumab by Race (D + T75 + SoC Arm; POSEIDON Study) (N=330)**

Race	IMFINZI (N=330)		Tremelimumab (N=330)	
	n	Patient-years exposure	n	Patient-years exposure
White	201	189.7	201	69.2
Asian	97	84.3	97	31.8
American Indian Or Alaska Native	11	9.5	11	3.7
Black or African American	8	11.4	8	3.9
Native Hawaiian Or Other Pacific Islander	2	0.6	2	0.4
Other	11	13.2	11	3.4
<b>Total</b>	<b>330</b>	<b>308.8</b>	<b>330</b>	<b>112.4</b>

Total exposure = Minimum of (last infusion/dose date of the last cycle + 20 days (if last infusion/dose date was during combination)/last infusion/dose date of the last cycle + 27 days (if last infusion/dose date was in maintenance or tremelimumab retreatment), date of death, date of DCO) – first infusion/dose date of first cycle + 1.

### II: 3.4 Exposure to IMFINZI ( $\pm$ Tremelimumab) for HCC

The pivotal safety dataset in support of the use of IMFINZI in combination with tremelimumab in patients with unresectable HCC was derived from pooled data from patients who received a single priming dose of tremelimumab 300 mg in combination with IMFINZI 1500 mg via iv infusion on Day 1 (Week 0) in the T300 + D arms of the HIMALAYA study (n = 388) and Study 22 (n = 74) (see [Table II-11](#) for details). After initial combination dosing, patients in both studies subsequently received IMFINZI 1500 mg monotherapy Q4W starting 4 weeks after the first and final infusion of the combination therapy until confirmed disease progression, unacceptable toxicity, or any discontinuation criterion was met.

The pivotal dataset in support of the use of IMFINZI as monotherapy in the same indication was derived from a pooled dataset of patients who received iv infusions of IMFINZI 1500 mg Q4W in the D arm of the HIMALAYA study (n = 388), and IMFINZI 1500 mg Q4W (n = 62) and 20mg/kg Q4W (n = 42) in Study 22 (see [Table II-11](#) for details). All patients received treatment until confirmed disease progression, unacceptable toxicity, or any discontinuation criterion was met.

Exposure to IMFINZI and tremelimumab (T300 + D) and IMFINZI (D) in the HCC tumour pool by weeks, age group and sex, and race is presented in [Table II-21](#), [Table II-22](#), and [Table II-23](#), respectively.

**Table II-21 Duration of Exposure to IMFINZI Monotherapy and in Combination with Tremelimumab (HCC Tumour Pool)**

Duration of exposure (weeks)	T300 + D (N = 462)				D (N = 492)	
	IMFINZI		Tremelimumab		n	Patient-years exposure
	n	Patient-years exposure	n	Patient-years exposure		
≥ 0	462	370.5	462	42.7	492	358.6
≥ 4	455	370.1	455	42.3	487	358.4
≥ 8	378	362.9	36	10.2	425	352.4
≥ 12	327	354.4	6	5.6	359	341.4
≥ 16	286	343.7	6	5.6	296	325.5
≥ 20	242	329.6	6	5.6	246	309.4
≥ 24	222	321.5	NA	NA	225	301.0
≥ 28	197	309.4	NA	NA	196	286.9
≥ 32	189	304.9	NA	NA	173	273.6
≥ 36	173	294.8	NA	NA	155	262.1
≥ 40	160	285.5	NA	NA	144	254.3
≥ 44	149	276.9	NA	NA	138	249.6
≥ 48	141	270.0	NA	NA	134	246.1
≥ 52	131	260.8	NA	NA	120	233.1
≥ 104	66	167.8	NA	NA	53	138.6
≥ 156	10	32.2	NA	NA	11	36.4

Total treatment duration = (last dose date + X days or death date or DCO whichever occurs earlier - first dose date +1/7, where X is defined as the planned frequency in dosing (in days) -1. For Q4W, X = 27.

**Table II-22 Exposure to IMFINZI Monotherapy and in Combination with Tremelimumab by Age Group and Sex (HCC Tumour Pool)**

Age group (years)	T300 + D (N = 462)								D (N = 492)			
	IMFINZI				Tremelimumab				Male		Female	
	Male		Female		Male		Female		Male		Female	
	n	PYE	n	PYE	n	PYE	n	PYE	n	PYE	n	PYE
< 65	193	153.1	33	19.3	193	16.5	33	3.0	208	145.0	46	31.0
≥ 65	194	160.3	42	37.8	194	20.0	42	3.3	205	159.9	33	22.8
<b>Total</b>	<b>387</b>	<b>313.4</b>	<b>75</b>	<b>57.1</b>	<b>387</b>	<b>36.4</b>	<b>75</b>	<b>6.3</b>	<b>413</b>	<b>304.8</b>	<b>79</b>	<b>53.8</b>

Total treatment duration = (last dose date + X days or death date or DCO whichever occurs earlier - first dose date +1/7, where X is defined as the planned frequency in dosing (in days) -1. For Q4W, X = 27.  
PYE, Patient years exposure.

**Table II-23 Exposure to IMFINZI Monotherapy and in Combination with Tremelimumab by Race (HCC Tumour Pool)**

Race	T300 + D (N = 462)				D (N = 492)	
	IMFINZI		Tremelimumab		n	Patient-years exposure
	n	Patient-years exposure	n	Patient-years exposure		
Asian	238	185.6	238	21.4	268	179.4
White	204	165.0	204	19.8	194	160.0
Black or African American	11	6.7	11	0.8	11	5.4
Other <sup>a</sup>	8	13.0	8	0.6	19	13.8
Missing	1	0.3	1	0.1	0	0
<b>Total</b>	<b>462</b>	<b>370.5</b>	<b>462</b>	<b>42.7</b>	<b>492</b>	<b>358.6</b>

<sup>a</sup> Other includes Multiple, American Indian or Alaska native and Native Hawaiian or other Pacific islander.  
Total treatment duration = (last dose date + X days or death date or DCO whichever occurs earlier - first dose date +1)/7, where X is defined as the planned frequency in dosing (in days) -1. For Q4W, X = 27.

### II: 3.5 Exposure to IMFINZI + EP for ES-SCLC

Data presented in this section are from the D + EP arm of the CASPIAN study (see [Table II-11](#) for details).

Exposure to IMFINZI in the D + EP arm of the CASPIAN study by weeks, age group and gender, and race is presented in [Table II-24](#), [Table II-25](#), and [Table II-26](#), respectively.

**Table II-24 Duration of Exposure to IMFINZI (D + EP Arm; CASPIAN Study) (N=265)**

Duration of exposure (weeks)	n	Patient-years exposure
≥0	265	167.3
≥8	242	166.0
≥16	223	161.7
≥24	166	139.6
≥32	108	109.7
≥40	77	88.7
≥48	52	67.9
≥50	51	67.0
≥52	46	62.0
<b>Total</b>	<b>265</b>	<b>167.3</b>

Total exposure = (last dose date + X days or death date or DCO whichever occurs earlier - first dose date +1) / 7. X is defined as the planned frequency in dosing (in days) - 1. For Caspian, if last dose is during EP, X = 20; if last dose is post-EP, X = 27.

**Table II-25 Exposure to IMFINZI by Age Group and Gender (D + EP Arm; CASPIAN Study) (N=265)**

Age group (years)	Male		Female	
	n	Patient-years exposure	n	Patient-years exposure
<65	113	69.2	51	34.4
≥65	75	45.1	26	18.7
<b>Total</b>	<b>188</b>	<b>114.3</b>	<b>77</b>	<b>53.1</b>

Total exposure = (last dose date + X days or death date or DCO whichever occurs earlier - first dose date +1) / 7. X is defined as the planned frequency in dosing (in days) - 1. For Caspian, if last dose is during EP, X = 20; if last dose is post-EP, X = 27.

**Table II-26 Exposure to IMFINZI by Race (D + EP Arm; CASPIAN Study) (N=265)**

Race	n	Patient-years exposure
White	226	148.0
Black or African American	2	1.4
Asian	36	17.5
Other	1	0.5
Missing	0	0.0
<b>Total</b>	<b>265</b>	<b>167.3</b>

Total exposure = (last dose date + X days or death date or DCO whichever occurs earlier - first dose date +1) / 7. X is defined as the planned frequency in dosing (in days) - 1. For Caspian, if last dose is during EP, X = 20; if last dose is post-EP, X = 27.

## II: 3.6 IMFINZI Monotherapy Exposure Across Indications

The studies included in the monotherapy pan-tumour pool are detailed in [Table II-11](#).

Exposure to IMFINZI monotherapy by weeks, age and gender, and race is presented in [Table II-27](#), [Table II-28](#), and [Table II-29](#), respectively.

**Table II-27 Duration of Exposure to IMFINZI Monotherapy (Pan-Tumour Pool) (N=3006)**

Duration of exposure (weeks)	n	Patient-years exposure
≥0	3006	1474.2
≥8	2248	1409.7
≥16	1554	1266.7
≥24	1221	1146.6
≥32	976	1020.3
≥40	836	927.2
≥48	718	830.4
≥50	685	799.5
≥52	567	683.2



**Table II-27 Duration of Exposure to IMFINZI Monotherapy (Pan-Tumour Pool)  
(N=3006)**

Duration of exposure (weeks)	n	Patient-years exposure
<b>Total</b>	<b>3006</b>	<b>1474.2</b>

Total exposure = (last dose date + X days or death date or DCO whichever occurs earlier - first dose date +1) / 7. X is defined as the planned frequency in dosing (in days) - 1. For studies with IMFINZI Q4W, X = 27. For studies with IMFINZI Q2W, X = 13.

**Table II-28 Exposure to IMFINZI Monotherapy by Age Group and Gender  
(Pan-Tumour Pool) (N=3006)**

Age group (years)	Male		Female	
	n	Patient-years exposure	n	Patient-years exposure
<65	1087	531.2	641	287.8
≥65	861	465.2	417	190.0
<b>Total</b>	<b>1948</b>	<b>996.4</b>	<b>1058</b>	<b>477.8</b>

Total exposure = (last dose date + X days or death date or DCO whichever occurs earlier - first dose date +1) / 7. X is defined as the planned frequency in dosing (in days) - 1. For studies with IMFINZI Q4W, X = 27. For studies with IMFINZI Q2W, X = 13.

**Table II-29 Exposure to IMFINZI Monotherapy by Race (Pan-Tumour Pool)  
(N=3006)**

Race	n	Patient-years exposure
White	2076	1028.1
Black or African American	67	31.6
Asian	739	357.3
Other	48	21.0
Missing	76	36.2
<b>Total</b>	<b>3006</b>	<b>1474.2</b>

Total exposure = (last dose date + X days or death date or DCO whichever occurs earlier - first dose date +1) / 7. X is defined as the planned frequency in dosing (in days) - 1. For studies with IMFINZI Q4W, X = 27. For studies with IMFINZI Q2W, X = 13.

## **II: 4 MODULE SIV: POPULATIONS NOT STUDIED IN CLINICAL TRIALS**

### **II: 4.1 Exclusion Criteria in Pivotal Clinical Studies Within the Development Program**

#### **Patients with prior Grade $\geq 3$ imAE while receiving immunotherapy, including anti-CTLA-4 treatment, or any unresolved imAE $>$ Grade 1**

Reason for exclusion: Patients with any prior Grade  $\geq 3$  imAE while receiving immunotherapy may be at a higher risk of recurrence of immune-mediated events of the same type.

Is it considered to be included as missing information: No

Rationale: The SmPC warns that this population has not been studied and/or that the effect of IMFINZI is unknown. As further characterisation of this population is neither feasible nor warranted, it is not relevant for inclusion as missing information.

#### **Patients requiring systemic immunosuppressive medication (except physiological dose of systemic corticosteroids) before starting IMFINZI**

Reason for exclusion: Systemic immunosuppressive medication pharmacologically impacts the different components of both the humoral and cell-mediated responses of the immune system. The impact on T cells may interfere with the MOA of IMFINZI.

Is it considered to be included as missing information: No

Rationale: This population was excluded for concerns regarding efficacy not safety. Experience to date has indicated that treatment with IMFINZI has been well tolerated by patients receiving physiological and high doses of systemic corticosteroids. Use of other immunosuppressive medications in the target population is not anticipated to lead to an increased risk of imAEs.

#### **Patients with pre-existing autoimmune disease**

Reason for exclusion: IMFINZI, by disrupting immune checkpoint function, can disturb mechanisms of immunologic tolerance that normally limit immune responses to healthy tissues, potentially leading to autoimmune-like/inflammatory side-effects or interference with down-regulation of immune responses to injury of normal tissue due to other causes (Naidoo et al 2015). IMFINZI has the potential to exacerbate underlying autoimmune diseases in patients who already have a diminished mechanism of immunologic tolerance.

Is it considered to be included as missing information: No

Rationale: The SmPC warns that this population has not been studied and/or that the effect of IMFINZI is unknown. As further characterisation of this population is neither feasible nor warranted, it is not considered relevant for inclusion as missing information.

### **Patients with untreated CNS metastatic disease, leptomeningeal disease, or cord compression**

Reason for exclusion: Patients with these conditions have significantly worse prognoses and are excluded in the initial clinical development to ensure interpretability of efficacy. However, patients with stable CNS metastases or cord compression are not excluded from IMFINZI clinical trials.

Is it considered to be included as missing information: No

Rationale: Based on the MOA of IMFINZI, components of the immune system (eg, T cells) are capable of crossing the blood brain barrier and possibly exerting an antitumour response. Consequently, this population was excluded for concerns regarding efficacy, not safety. Patients previously treated for CNS metastases that are radiographically and neurologically stable and do not require corticosteroids (of any dose) for symptomatic management for at least 14 days prior to the first dose of IMFINZI are included in clinical trials with IMFINZI. No evidence of a different safety profile in patients with stable CNS metastases has been evident in the clinical development program to date, and the further investigation of IMFINZI in patients with untreated metastatic CNS disease, leptomeningeal disease, or cord compression is not feasible due to the poor prognosis in this patient population.

### **Paediatric and adolescent patients <18 years of age**

Reason for exclusion: This population was excluded from this clinical trial program based on the general principle that paediatric patients are not exposed to the investigational product where the benefit-risk profile for the intended adult population has not yet been established.

Is it considered to be included as missing information: No

Rationale: Paediatrics and adolescents are out of scope for the target indications, as these are primarily diseases of adults, with only exceptional occurrence in the paediatric population (Dishop and Kuruvilla 2008, Karatzas and Tzortzis 2019, Khanna and Verma 2018, Newsome et al 2018).

### **Females who are pregnant or lactating**

Reason for exclusion: It is unknown whether IMFINZI is secreted in human milk, and pregnant and lactating females are excluded to avoid potential harm to the unborn foetus or breastfeeding newborn.

Is it considered to be included as missing information: No

Rationale: The SmPC warns that this population has not been studied and/or that the effect of IMFINZI is unknown. As further characterisation of this population is neither feasible nor warranted, it is not considered relevant for inclusion as missing information.

### **Patients with active primary immunodeficiency**

Reason for exclusion: IMFINZI treatment may not be effective due to underlying immune deficiency.

Is it considered to be included as missing information: No

Rationale: The safety profile is not expected to be less favourable for patients with primary immune deficiency than in the intended population because, by their MOA, immune checkpoint inhibitors can only alter existing immune mechanisms.

### **Patients with pre-existing active infection/co-infection including tuberculosis, hepatitis B, hepatitis C, or HIV**

Reason for exclusion: PD-L1 blockade could lead to an initial exacerbation of the underlying infectious disease or systemic inflammatory response.

Is it considered to be included as missing information: No

Rationale: The SmPC warns that this population has not been studied and/or that the effect of IMFINZI is unknown. As further characterisation of this population is neither feasible nor warranted, it is not considered relevant for inclusion as missing information.

### **Patients receiving live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving IMFINZI**

Reason for exclusion: This population is excluded due to concern of live attenuated vaccine complications. PD-1/PD-L1 blockade could lead to more vigorous inflammation. In analogy, immune reconstitution in HIV patients was associated with BCG vaccine complications ([Nuttall et al 2008](#)).

Is it considered to be included as missing information: No

Rationale: The SmPC warns that this population has not been studied and/or that the effect of IMFINZI is unknown. As further characterisation of this population is neither feasible nor warranted, it is not considered relevant for inclusion as missing information.

## **II: 4.2 Limitations to Detect Adverse Reactions in Clinical Trial Development Programs**

The clinical development program is unlikely to detect certain types of adverse reactions such as rare adverse reactions or adverse reactions with a long latency.

## II: 4.3 Limitations in Respect to Populations Typically Under-Represented in Clinical Trial Development Programs

**Table II-30 Exposure of Special Populations Included or Not in Clinical Trial Development Programs**

Type of special population	Exposure (number of patients)							
	IMFINZI monotherapy pan-tumour pool <sup>a</sup>	CASPIAN (D + EP)	POSEIDON (D + T75 + SoC)	HCC tumour pool		TOPAZ-1 (D + Gem/Cis)	DUO-E	
				T300 + D	D		SoC + D	SoC + D + O
Pregnant women	Not included in the clinical development program							
Breastfeeding women								
Patients with relevant comorbidities:								
Moderate hepatic impairment <sup>b</sup>	9	1	1	4	20	16	2	0
Severe hepatic impairment <sup>b</sup>	2	0	0	0	0	0	0	0
Severe renal impairment <sup>c</sup>	3	0	0	1	0	0	0	0
Patients with uncontrolled cardiovascular disorders (including congestive heart failure, hypertension, unstable angina, or cardiac arrhythmia)	Not included in the clinical development program.							
Patients with active autoimmune diseases requiring systemic immunosuppressive treatment	Not included in the clinical development program.							
Patients with relevant different ethnic origin:								
Black or African American	67	2	8	11	11	8	11	14
Asian	739	36	97	238	268	184	71	69
Other <sup>d</sup>	48	1	11	8	19	17	14	19
Subpopulations carrying relevant genetic polymorphisms	No data are available regarding relevant genetic polymorphisms.							

<sup>a</sup> The studies included in the IMFINZI monotherapy pan-tumour pool and their data cut-off dates are summarised in [Table II-11](#).

<sup>b</sup> The definitions for hepatic impairment are as follows: normal hepatic function = BIL ≤ULN and AST ≤ULN; mild hepatic impairment = BIL ≤ULN and AST >ULN or BIL >1 to 1.5 × ULN and any AST; moderate hepatic impairment = BIL >1.5 to 3 × ULN and any AST; and severe hepatic impairment = BIL >3 × ULN and any AST (where ULN of BIL is 1.9 IU/L and ULN of AST is 34 IU/L).

<sup>c</sup> The definitions for renal impairment are as follows: normal renal function: CrCL ≥90 mL/min, mild renal impairment: CrCL = 60 to 89 mL/min, moderate renal impairment: CrCL = 30 to 59 mL/min, and severe renal impairment: CrCL = 15 to 29 mL/min.

<sup>d</sup> Other includes Multiple, American Indian or Alaska native and Native Hawaiian or other Pacific islander.

## **II: 5 MODULE SV: POST-AUTHORISATION EXPERIENCE**

### **II: 5.1.1 Method Used to Calculate Exposure**

The postmarketing patient exposure data presented is estimated based on monthly actual ex-factory sales volume from each local marketing company. These data represent all IMFINZI formulation delivered to various distribution channels (for example wholesalers, pharmacies etc) worldwide.

The sales volume is provided as the total sales in mg, calculated by number of vials sold multiplied by strength of formulation. The approved strengths and dosage forms for this product are 500 mg/10 mL (50 mg/mL) and 120 mg/2.4 mL (50 mg/mL) solutions for iv infusion. The recommended dose as per the Core Data Sheet for the indications of UC and NSCLC is 10 mg/kg administered as an iv infusion over 60 minutes Q2W as long as clinical benefit is observed or until unacceptable toxicity for UC patients or until disease progression or unacceptable toxicity for locally advanced NSCLC patients. Assuming the average patient weight is 75 kg the dose becomes  $75 \times 10 = 750$  mg/60 mins/2 weeks. To calculate the patient exposure both the sales figures and recommended dose should be in the same units. Hence, below is the methodology for converting the recommended dose to mg:

- 1 year has 365 days and 52 weeks ( $365/7 = 52$  weeks)
- Since recommended dose is given Q2W hence, number of weeks' patient is exposed to drug is 26 weeks ( $52/2 = 26$  weeks)
- If in 2 weeks, the patient is exposed to 750 mg then in 26 weeks the patient is exposed to 19500 mg ( $750 \times 26 = 19500$  mg). Therefore, the recommended dose as per the label is 19500 mg in a year.
- Number of patient-years = sales in mg divided by recommended dose 19500 mg.

Although a flat dose regimen is also recommended for locally-advanced NSCLC, UC and HCC patients (1500 mg Q4W) and alternative dosing regimens are used for patients receiving IMFINZI for metastatic NSCLC, ES-SCLC, and BTC (see [Table I-1](#) for details), these regimens are not incorporated into exposure calculations to maintain consistency with previous data.

The current methodology does not distinguish between sales that are related to initial prescriptions versus those related to repeat prescriptions. Therefore, it is not possible to estimate the number of patients exposed to IMFINZI. Detailed patient-level data (eg, gender, ethnicity, age category, off-label use, specific populations etc) are not available.

### **II: 5.1.2 Exposure**

The cumulative global post-marketing patient exposure to IMFINZI (10 mg/kg), since launch to 30 April 2023, has been estimated to be approximately 118467 patient-years.

## **II: 6      MODULE SVI: ADDITIONAL EU REQUIREMENTS FOR THE SAFETY SPECIFICATION**

### **Potential for misuse for illegal purposes**

IMFINZI is a potent and highly selective human IgG1 $\kappa$  mAb designed to inhibit binding of PD-L1 to PD-1 and CD80. Based on its clinical setting of use, mode of action, physiological and pharmacological activity, and lack of stimulant and addictive properties, IMFINZI is unlikely to be abused.

## II: 7 MODULE SVII: IDENTIFIED AND POTENTIAL RISKS

### II: 7.1 Identification of Safety Concerns in the Initial RMP Submission

#### II: 7.1.1 Risk Not Considered Important For Inclusion in the List of Safety Concerns in the RMP

##### Reasons for not including an identified or potential risk in the list of safety concerns in the RMP

Risks with minimal clinical impact on patients (in relation to the severity of the indication treated) include abdominal pain, cough/productive cough, dental and oral soft tissue infections, dysphonia, dysuria, influenza, myalgia, night sweats, oedema peripheral, oral candidiasis, pyrexia, and upper respiratory tract infections.

Pneumonia as a risk is not considered important because only low-grade events were more prevalent in the IMFINZI group compared to the placebo group. Low-grade events are not considered to impact the benefit-risk for IMFINZI in the target population.

There is potential risk of medication error for IMFINZI as a consequence of the different doses and frequency of administration specific to the 2 lung cancer indications. IMFINZI should be administered to NSCLC patients using a weight-based dose (10 mg/kg Q2W) and to ES-SCLC patients using a fixed dose (1500 mg) (Table II-31). The fixed dose of 1500 mg Q4W (equivalent to 20 mg/kg Q4W for an average body weight of 75 kg) is predicted to result in similar area under the concentration-time curve and only a modest difference in median peak and trough levels at steady state compared to 10 mg/kg Q2W based on population pharmacokinetics simulations. Therefore, the fixed dose is expected to demonstrate similar efficacy and safety profiles to the 10 mg/kg Q2W regimen. As the weight-based and fixed-dose regimens have shown similar safety profiles, the risk to the patient, should they receive the incorrect dosing regimen, is low.

In addition, the potential risk for medication error due to differences in frequency of IMFINZI administration between patients with NSCLC and ES-SCLC could eventually lead to under- or over-dosing. However, this risk is considered low because for patients with ES-SCLC, the difference in frequency of IMFINZI administration is driven by coadministration of chemotherapy.

**Table II-31 IMFINZI Dosing and Duration of Therapy**

Indication	Recommended IMFINZI dose	Duration of therapy
Locally advanced NSCLC	10 mg/kg every 2 weeks	Until disease progression, unacceptable toxicity, or a maximum of 12 months <sup>a</sup>



**Table II-31 IMFINZI Dosing and Duration of Therapy**

Indication	Recommended IMFINZI dose	Duration of therapy
ES-SCLC	1500 mg <sup>b</sup> in combination with chemotherapy <sup>c,d</sup> every 3 weeks (21 days) for 4 cycles, followed by 1500 mg every 4 weeks as monotherapy	Until disease progression or unacceptable toxicity

<sup>a</sup> It is recommended to continue treatment for clinically stable patients with initial evidence of disease progression until disease progression is confirmed.

<sup>b</sup> Patients with a body weight of 30 kg or less must receive weight-based dosing, equivalent to IMFINZI 20 mg/kg in combination with chemotherapy every 3 weeks (21 days) for 4 cycles, followed by 20 mg/kg every 4 weeks as monotherapy until weight increases to greater than 30 kg.

<sup>c</sup> Administer IMFINZI prior to chemotherapy on the same day.

<sup>d</sup> When IMFINZI is administered in combination with chemotherapy, refer to the Prescribing Information for etoposide and carboplatin or cisplatin for dosing information.

Source: IMFINZI SmPC.

The IMFINZI container label has been carefully designed to reduce confusion regarding product concentration, content, instructions for diluting with water, and the administration rate. Moreover, IMFINZI is not a self-administered medication, rather, it is to be administered as an iv infusion by highly trained, specialised healthcare professionals familiar with iv administration procedure. Therefore, the risk of medication error for IMFINZI is expected to be low and without significant impact on the overall benefit risk profile of IMFINZI.

Medication errors will be reviewed through routine pharmacovigilance.

Obesity is viewed as a critical co-factor in cancer due to metabolic, inflammatory and immune perturbations (Mirsoian and Murphy 2015, Canter et al 2018). The evidence for an impact of obesity on safety outcomes with immunotherapies is, however, limited at this time. Based on patients with reported BMI in the exposure-safety analysis population (Study 1108, PACIFIC; n=1324), 17.4% (n=230) of patients were classified as obese, based on BMI of = 30. Higher IMFINZI exposure was observed in obese patients when compared to other BMI subgroups; however, there is no evidence of a different safety profile. An analysis across the pooled dataset assessed 3 safety endpoints (Grade 3 or 4 drug-related adverse event, Grade 3 or 4 drug-related adverse events of special interest and adverse event leading to treatment discontinuation) for all BMI subgroups. The results show that adverse event incidence rates were comparable across BMI subgroups for all 3 safety endpoints; therefore, safety data do not suggest an unfavourable impact on benefit-risk profile for the obese subpopulation.

## **II: 7.1.2 Risks considered important for inclusion in the list of safety concerns in the RMP**

**Important identified risks: immune-mediated adverse events of pneumonitis, hepatitis, colitis or diarrhoea, hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis or hypopituitarism, type 1 diabetes mellitus, nephritis, and rash or dermatitis.**

### **Benefit-risk impact:**

Overall, Grade 3/4 imAEs and fatal outcomes were observed in 2.4% and 0.4% of patients, respectively, treated with IMFINZI monotherapy. Although severe imAEs are of low frequency or rare, they can be potentially serious or life-threatening for the individual patient and require careful monitoring, early recognition and timely intervention by withholding/discontinuation of IMFINZI, and appropriate medical intervention, including systemic corticosteroids and/or hormone replacement therapy.

### **Important identified risk: Infusion-related reaction**

#### **Benefit-risk impact:**

Severe or life-threatening infusion-related reaction may result in the need to interrupt or permanently discontinue IMFINZI therapy and requires careful monitoring, early recognition, and timely intervention.

### **Important potential risk: Immune-mediated pancreatitis**

#### **Benefit-risk impact:**

Immune-mediated pancreatitis is associated with other anti-PD-1/PD-L1 agents and is being closely monitored in the IMFINZI program and is observed rarely. Pancreatitis can be potentially serious or life-threatening in the individual patient, and requires careful monitoring, early recognition and timely intervention by withholding/discontinuation of IMFINZI and appropriate medical intervention including systemic corticosteroids.

### **Important potential risk: Other potential immune-mediated adverse reactions (eg, myasthenia gravis and Guillain-Barré syndrome)**

#### **Benefit-risk impact:**

Serious and rare risks of myasthenia gravis and Guillain-Barré syndrome are associated with other anti-PD-1/PD-L1 agents. Cases of myasthenia gravis and Guillain-Barré syndrome have been reported and are being closely monitored in the IMFINZI program. Other potential immune-mediated adverse reactions, such as myasthenia gravis and Guillain-Barre syndrome, can be potentially serious or life threatening in the individual patient, and require careful monitoring, early recognition and timely intervention by withholding/discontinuation of IMFINZI and appropriate medical intervention including systemic corticosteroids.

**Missing information: Patients with moderate or severe hepatic impairment**

**Benefit-risk impact:**

There has been low exposure of patients with moderate or severe hepatic impairment in clinical trials. Data in these populations will be important to further understand the safety profile of IMFINZI.

**Missing information: Patients with severe renal impairment**

**Benefit-risk impact:**

There has been low exposure of patients with severe renal impairment in clinical trials. Data in these populations will be important to further understand the safety profile of IMFINZI.

**Missing information: Patients with prior Grade  $\geq 3$  imAE while receiving immunotherapy, including anti-CTLA-4 treatment or any unresolved imAE  $>$ Grade 1**

**Benefit-risk impact:**

These patients may be at a higher risk of recurrence of immune-mediated events of the same type. Data in these populations will be important to further understand the safety profile of IMFINZI.

**Missing information: Patients with pre-existing autoimmune disease**

**Benefit-risk impact:**

Patients with pre-existing autoimmune disease other than vitiligo, alopecia, hypothyroidism stable on hormone replacement, or chronic skin conditions not requiring systemic treatment were excluded from clinical studies. It is anticipated that treatment with IMFINZI could exacerbate pre-existing autoimmune diseases, with potentially detrimental consequences that lead to an unacceptable benefit-risk profile. Data in these populations will be important to further understand the safety profile of IMFINZI.

**Missing information: Patients with pre-existing active infection including tuberculosis, hepatitis B, hepatitis C, or HIV**

**Benefit-risk impact:**

These patients may be at risk of exacerbation of underlying infectious diseases or systemic inflammatory responses. Data in these populations will be important to further understand the safety profile of IMFINZI.

**Missing information: Patients receiving live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving IMFINZI**

**Benefit-risk impact:**

These patients may be at risk of vaccine complications. Data in these populations will be important to further understand the safety profile of IMFINZI. In analogy, immune

reconstitution in HIV patients was associated with BCG vaccine complications ([Nuttall et al 2008](#)).

**Missing information: Female patients who are pregnant or breastfeeding**

**Benefit-risk impact:**

Due to its mechanism of action, IMFINZI could potentially cause foetal harm when administered to a pregnant woman. It is unknown if IMFINZI is secreted in human milk but a risk to newborns/infants from breastfeeding women cannot be excluded. Use in this population is not anticipated due to recommendations in the label not to use during pregnancy or when breastfeeding.

**II: 7.2 New Safety Concerns and Reclassification with a Submission of an Updated RMP**

There are no new safety concerns or reclassifications of safety concerns.

**II: 7.3 Details of Important Identified Risks, Important Potential Risks, and Missing Information**

There are no safety concerns.

## **II: 8      MODULE SVIII: SUMMARY OF THE SAFETY CONCERNS**

### **II: 8.1    Summary of the Safety Concerns**

There are no safety concerns.

### **III: PART III: PHARMACOVIGILANCE PLAN**

#### **III: 1 ROUTINE PHARMACOVIGILANCE ACTIVITIES**

There are no safety concerns, so only routine pharmacovigilance activities are required.

#### **III: 2 ADDITIONAL PHARMACOVIGILANCE ACTIVITIES**

No additional pharmacovigilance activities are proposed.

#### **III: 3 SUMMARY TABLE OF ADDITIONAL PHARMACOVIGILANCE ACTIVITIES**

Not applicable.

## IV: PART IV: PLANS FOR POST-AUTHORISATION EFFICACY STUDIES

A summary of the planned and ongoing post-authorisation efficacy studies that are conditions of the marketing authorisation or are specific obligations is provided in [Table IV-1](#).

**Table IV-1 Planned and Ongoing Post-Authorisation Efficacy Studies that are Conditions of the Marketing Authorisation or are Specific Obligations**

Study code (name) / Short title Status	Summary of objectives	Efficacy uncertainties addressed	Milestones	Due dates for EMA
<b>Efficacy studies which are conditions of the marketing authorisation</b>				
<b>Study D9311C00001 (DUO-E)</b> A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer. • <b>Status:</b> Ongoing	<u>Primary Objective:</u> • To demonstrate the efficacy of SoC + D or SoC + D + O when compared to SoC by assessment of PFS.  <u>Secondary Objective:</u> • To determine the efficacy of SoC + D or SoC + D + O when compared to SoC by the assessment of PFS2, OS, ORR, DoR, TFST, TSST, and TDT.	• Further evidence of efficacy and safety in patients with advanced and recurrent endometrial cancer in the first-line treatment setting	Interim OS analysis	Q4 2025
			Final report	Q4 2026
<b>Efficacy studies which are Specific Obligations in the context of a conditional marketing authorisation or a marketing authorisation under exceptional circumstances</b>				
Not applicable				

DoR, Duration of response; ORR, Objective response rate; OS, Overall survival; PFS, Progression-free survival; PFS2, Second progression-free survival; TDT, Time to treatment discontinuation or death; TFST, Time to first subsequent therapy or death, TSST, Time to second subsequent therapy or death.

**V: PART V: RISK MINIMISATION MEASURES**

**V: 1 ROUTINE RISK MINIMISATION MEASURES**

Not applicable as there are no safety concerns.

**V: 2 ADDITIONAL RISK MINIMISATION MEASURES**

Not applicable as there are no safety concerns.

**V: 3 SUMMARY OF RISK MINIMISATION MEASURES**

Not applicable as there are no safety concerns.



## **VI: PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN FOR IMFINZI (DURVALUMAB)**

This is a summary of the Risk Management Plan (RMP) for IMFINZI (durvalumab). The RMP details important risks of IMFINZI, how these risks can be minimised, and how more information will be obtained about IMFINZI's risks and uncertainties (missing information).

IMFINZI's Summary of Product Characteristics (SmPC) and its package leaflet (PL) give essential information to healthcare professionals and patients/carers on how IMFINZI should be used.

This summary of the RMP for IMFINZI should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all of which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of IMFINZI's RMP.

### **VI: 1 THE MEDICINE AND WHAT IT IS USED FOR**

IMFINZI is authorised:

- As monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express programmed cell death ligand 1 (PD-L1) on  $\geq 1\%$  of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy.
- In combination with etoposide and either carboplatin or cisplatin for the first-line treatment of adults with extensive-stage small cell lung cancer.
- In combination with gemcitabine and cisplatin for the first-line treatment of adults with unresectable or metastatic biliary tract cancer.
- In combination with tremelimumab and platinum-based chemotherapy for the first-line treatment of adults with metastatic NSCLC with no sensitising epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) positive mutations.
- In combination with tremelimumab for the first-line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).
- As monotherapy for the first-line treatment of adults with advanced or unresectable HCC.

- In combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with:
  - IMFINZI as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)
  - IMFINZI in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).

IMFINZI contains durvalumab as the active substance and is administered as an intravenous infusion.

Further information about the evaluation of IMFINZI's benefits can be found in IMFINZI's EPAR, including its plain-language summary, available on the European Medicines Agency website, under the medicine's webpage:

<https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi>.

## **VI: 2 RISKS ASSOCIATED WITH THE MEDICINE AND ACTIVITIES TO MINIMISE OR FURTHER CHARACTERISE THE RISKS**

Important risks of IMFINZI, together with measures to minimise such risks and the proposed studies for learning more about risks of IMFINZI, are outlined below.

Measures to minimise the risks identified for medicinal products can be as follows:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and product information addressed to patients and healthcare professionals
- Important advice on the medicine's packaging
- The authorised pack size — the amount of medicine in a pack is chosen to ensure that the medicine is used correctly
- The medicine's legal status — the way a medicine is supplied to the patient (eg, with or without prescription) can help to minimise its risks

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including Periodic Safety Update Report assessment, so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

## **VI: 2.1 List of Important Risks and Missing Information**

Important risks of IMFINZI are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of IMFINZI. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (eg, on the long-term use of the medicine).

There are no safety concerns for IMFINZI.

## **VI: 2.2 Summary of Important Risks**

There are no safety concerns for IMFINZI.

## **VI: 2.3 Post-authorisation Development Plan**

### **VI: 2.3.1 Studies that are Conditions of the Marketing Authorisation**

The following study is a condition of the marketing authorisation:

- **Study D9311C00001 (DUO-E) - A study to assess the efficacy and safety of IMFINZI in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance IMFINZI with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer**
  - *Purpose of the study:* To investigate the efficacy of IMFINZI in combination with standard-of-care platinum-based chemotherapy (carboplatin and paclitaxel) followed by IMFINZI with or without olaparib, compared to standard-of-care platinum-based chemotherapy, by the assessment of progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer.

### **VI: 2.3.2 Other Studies in the Post-Authorisation Development Plan**

There are no studies required for IMFINZI.

## LIST OF REFERENCES

### **Aarts et al 2015**

Aarts MJ, Aerts JG, van den Borne BE, Biesma B, Lemmens VE, Kloover JS. Comorbidity in Patients With Small-Cell Lung Cancer: Trends and Prognostic Impact. *Clin Lung Cancer* 2015;16:282-91.

### **Adambekov et al 2019**

Adambekov S, Yi Y, Fabio A, Miljkovic I, Edwards RP, Lopa S, et al. Metabolic syndrome in endometrial cancer patients: systematic review. *Metab Syndr Relat Disord*. 2019;17(5):241-9.

### **Anderson et al 2022**

Anderson C, Olshan AF, Bae-Jump VL, Brewster WR, Lund JL, Nichols HB. Cardiovascular disease diagnoses among older women with endometrial cancer. *Gynecol Oncol*. 2022;1;167(1):51-7.

### **Alberg et al 2007**

Alberg AJ, Ford JG, Samet JM; American College of Chest Physicians. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest* 2007;132:29S-55S.

### **Alvarado-Luna and Morales-Espinosa 2016**

Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now?-a review. *Transl Lung Cancer Res* 2016;5:26-38.

### **American Cancer Society 2019**

American Cancer Society. Lung cancer. Available from URL: <https://www.cancer.org/cancer/lung-cancer.html>. Accessed on: 08 July 2019.

### **American Cancer Society 2021**

American Cancer Society. Facts and Figures 2021. American Cancer Society. Atlanta, GA.2021. Available at: <https://cancerstatisticscenter.cancer.org>.

### **Arora et al 2016**

Arora A, Rajesh S, Bansal K, Sureka B, Patidar Y, Thapar S, et al. Cirrhosis-related musculoskeletal disease: radiological review. *Br J Radiol*. 2016 Oct;89(1066):20150450.

### **Asrani et al 2019**

Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. *J Hepatol*. 2019 Jan;70(1):151-171.

### **Balogh et al 2016**

Balogh J, Victor D 3rd, Asham EH, Burroughs SG, Boktour M, Saharia A, et al. Hepatocellular carcinoma: a review. *J Hepatocell Carcinoma*. 2016 Oct 5;3:41-53.

**Banales et al 2020**

Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. *Nat Rev Gastroenterol Hepatol*. 2020;17(9):557-88.

**Bittoni et al 2018**

Bittoni MA, Arunachalam A, Li H, Camacho R, He J, Zhong Y, Lubiniecki GM, Carbone DP. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study. *Clin Lung Cancer*. 2018 Sep; 19(5): e629-e645. doi: 10.1016/j.clcc.2018.04.017.

**Bonafede et al 2020**

Bonafede MM, Korytowsky B, Singh P, Cai Q, Cappell K, Jariwala-Parikh K, et al. Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy. *J Gastrointest Cancer*. 2020 Mar;51(1):217-226.

**Bray et al 2005**

Bray F, Loos AH, Oostindier M, Weiderpass E. Geographic and temporal variations in cancer of the corpus uteri: incidence and mortality in pre-and post-menopausal women in Europe. *Int J Cancer*. 2005;117(1):123-31.

**Bray et al 2018**

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68:394-424.

**Bridgewater et al 2016**

Bridgewater JA, Goodman KA, Kalyan A, Mulcahy MF. Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling. *Am Soc Clin Oncol Educ Book*. 2016;35:e194–203.

**Butt et al 2012**

Butt Z, Parikh ND, Beaumont JL, Rosenbloom SK, Syrjala KL, Abernethy AP, et al. Development and validation of a symptom index for advanced hepatobiliary and pancreatic cancers: the National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (NCCN-FACT) Hepatobiliary-Pancreatic Symptom Index (NFHSI). *Cancer* 2012;118(23):5997-6004.

**Cabibbo et al 2010**

Cabibbo G, Antonucci M, Genco C. Update on new approaches in the management of hepatocellular carcinoma. *Hepat Med*. 2010 Nov 26;2:163-73.

**Caldwell and Park 2009**

Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. *J Gastroenterol*. 2009;44 Suppl 19:96-101.

**Canter et al 2018**

Canter RJ, Aguilar E, Wang Z, Le C, et al. Obesity results in higher PD-1-mediated T-cell suppression but greater T-cell effector functions following blockade. *Journal of Clinical Oncology* 36, no. 5\_suppl (February 10 2018) 65-65. doi: 10.1200/JCO.2018.36.5\_suppl.65

**Cao et al 2011**

Cao J, Yang C, Li J, Chen R, Chen B, Gu D, Kan H. Association between long-term exposure to outdoor air pollution and mortality in China: a cohort study. *J Hazard Mater* 2011;186:1594-600.

**Centers for Disease Control and Prevention 2018**

Centers for Disease Control and Prevention. Liver and Intrahepatic Bile Ducts Cancers, United States—2006–2015. USCS data brief, no 5. Atlanta, GA: Centers for Disease Control and Prevention; 2018. Available at: <https://www.cdc.gov/cancer/uscs/pdf/USCS-DataBrief-No5-November2018-508.pdf>. Accessed 04 November 2022.

**Connaughton and Dabagh 2022**

Connaughton M, Dabagh M. Association of hypertension and organ-specific cancer: a meta-analysis. *Healthcare*. 2022;10(6):1074.

**Creasman et al 2006**

Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. *Int J Gynaecol Obstet*. 2006;95 Suppl 1:S105-43.

**Crosbie et al 2022**

Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. *Lancet*. 2022;399(10333):1412-28.

**Crvenkova 2018**

Crvenkova S. Survival and Side Effects in Non-Small Cell Lung Cancer Patients Treated With Combination of Chemotherapy and Conformal Radiotherapy. *Open Access Maced J Med Sci* 2018;6:2323-2327.

**D'Addio et al 2011**

D'Addio F, Riella LV, Mfarrej BG, Chabtini L, Adams LT, Yeung M, et al. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. *J Immunol* 2011;187:4530-41.

### **Darwisch et al 2013**

Darwisch Murad S, Heimbach JK, Gores GJ, Rosen CB, Benson JT, Kim WR. Excellent quality of life after liver transplantation for patients with perihilar cholangiocarcinoma who have undergone neoadjuvant chemoradiation. *Liver Transpl* 2013;19(5):521-8.

### **Decision Resources Group 2018**

Decision Resources Group. Biopharma. Available from URL: <https://decisionresourcesgroup.com/research-reports/biopharma/>. Accessed on: 08 July 2019.

### **Dishop and Kuruvilla 2008**

Dishop MK and Kuruvilla S. Primary and metastatic lung tumors in the pediatric population: a review and 25-year experience at a large children's hospital. *Arch Pathol Lab Med* 2008;132:1079-103.

### **EASL 2018**

European Association for the Study of the Liver (EASL). Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol* 2018;69(1):182-236.

### **Eckel and Schmid 2007**

Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. *Br J Cancer*. 2007 Mar 26;96(6):896-902.

### **Edwards et al 2014**

Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. Annual report to the nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. *Cancer* 2014;120:1290-314.

### **El Serag 2012**

El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. *Gastroenterology*. 2012 May;142(6):1264-1273.e1.

### **El-Serag and Rudolph 2007**

El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology*. 2007 Jun;132(7):2557-76.

### **Elberg Dengsø et al 2017**

Elberg Dengsø K, Hillingsø J, Marcussen AM, Thomsen T. Health-related quality of life and anxiety and depression in patients diagnosed with cholangiocarcinoma: a prospective cohort study. *Acta Oncol*. 2017;56(2):198-204.

### **FDA 2019**

United States Food and Drug Administration (FDA). FDA approves atezolizumab for extensive-stage small cell lung cancer. Available from URL: <https://www.fda.gov/drugs/drug->

approvals-and-databases/fda-approves-atezolizumab-extensive-stage-small-cell-lung-cancer.  
Accessed on: 20 September 2019.

**Ferlay et al 2015**

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*. 2015;136(5):E359-86.

**Fernández-Ruiz et al 2009**

Fernández-Ruiz M, Guerra-Vales JM, Colina-Ruizdelgado F. Comorbidity negatively influences prognosis in patients with extrahepatic cholangiocarcinoma. *World J Gastroenterol*. 2009 Nov 14;15(42):5279-86.

**Furau et al 2021**

Furau A, Tit DM, Furau C, Bungau S, Furau G, Toma MM, et al. Analysis of the impact of comorbidities on endometrial lesions using the Charlson comorbidity index in Western Romania. *Medicina*. 2021;57(9):945.

**GBD 2016**

GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016 Oct 8;388(10053):1545-1602.

**Ghidini et al 2019**

Ghidini M, Pizzo C, Botticelli A, Hahne JC, Passalacqua R, Tomasello G, et al. Biliary tract cancer: current challenges and future prospects. *Cancer Manag Res*. 2019;11:379–88.

**Gray et al 2009**

Gray A, Read S, McGale P, Darby S. Lung cancer deaths from indoor radon and the cost effectiveness and potential of policies to reduce them. *BMJ* 2009;338:a3110.

**Guleria et al 2005**

Guleria I, Khosroshahi A, Ansari MJ, Habicht A, Azuma M, Yagita H, et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance. *J Exp Med* 2005;202:231-7.

**Hales et al 2012**

Hales S, Blakely T, Woodward A. Air pollution and mortality in New Zealand: cohort study. *J Epidemiol Community Health* 2012;66:468-73.

**Halla 2022**

Halla K. Emerging treatment options for advanced or recurrent endometrial cancer. *J Adv Pract Oncol*. 2022;13(1):45-59.



**Heffernan et al 2002**

Heffernan N, Cella D, Webster K, Odom L, Martone M, Passik S, et al. Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. *J Clin Oncol* 2002; 20(9): 2229–2239

**Institute for Health Metrics and Evaluation 2016**

IHME - Global Burden of Disease Study 2016 (GBD 2016) Data Resources. Available at: <http://ghdx.healthdata.org/gbd-2016>.

**Institute for Health Metrics and Evaluation 2017**

IHME - Global Burden of Disease Study 2017 (GBD 2017) Data Resources. Available at: <http://ghdx.healthdata.org/gbd-2017>.

**International Agency for Research on Cancer 2021**

Europe facts sheet, 2021. Available from URL: <https://gco.iarc.fr/today/data/factsheets/populations/908-europe-fact-sheets.pdf> Accessed 31 July 2023.

**Janevska et al 2015**

Janevska D, Chaloska-Ivanova V, Janevski V. Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment. *Open Access Maced J Med Sci*. 2015 Dec 15;3(4):732-6.

**JSH 2021**

Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. *Liver Cancer* 2021;10:181-223.

**Jung et al 2012**

Jung SJ, Woo SM, Park HK, Lee WJ, Han MA, Han SS, et al. Patterns of initial disease recurrence after resection of biliary tract cancer. *Oncology*. 2012;83(2):83-90.

**Kantar Health 2018**

CancerMPact® NSCLC, Patient Metrics. Kantar. Available from URL: [www.cancermpact.com](http://www.cancermpact.com). Accessed on: 08 July 2019.

**Karatzas and Tzortzis 2019**

Karatzas A, Tzortzis V. Lower urinary tract symptoms and bladder cancer in children: The hidden scenario. *Urol Ann* 2019;11(1):102-104.

**Katanoda et al 2011**

Katanoda K, Sobue T, Satoh H, Tajima K, Suzuki T, Nakatsuka H, Takezaki T, Nakayama T, Nitta H, Tanabe K, Tominaga S. An association between long-term exposure to ambient air pollution and mortality from lung cancer and respiratory diseases in Japan. *J Epidemiol* 2011;21:132-43.

**Khanna and Verma 2018**

Khanna R, Verma SK. Pediatric hepatocellular carcinoma. *World J Gastroenterol* 2018;21;24(35):3980-3999.

**Lamarca et al 2014**

Lamarca A, Hubner RA, Ryder WD, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. *Ann Oncol*. 2014;25(12):2328-38.

**Lee et al 2018a**

Lee HY, Kim EY, Kim YS, Ahn HK, Kim YK. Prognostic significance of CT-determined emphysema in patients with small cell lung cancer. *J Thorac Dis* 2018;10:874-881.

**Lee et al 2018b**

Lee KT, Lin JJ, Shi HY. Anxiety and depression are associated with long-term outcomes of hepatocellular carcinoma: A nationwide study of a cohort from Taiwan. *World J Biol Psychiatry*. 2018 Sep;19(6):431-439.

**Linares et al 2016**

Linares I, Molina-Portillo E, Expósito J, Baeyens JA, Suárez C, Sánchez MJ. Trends in lung cancer incidence by histologic subtype in the south of Spain, 1985-2012: a population-based study. *Clin Transl Oncol* 2016;18:489-96.

**Lissowska et al 2010**

Lissowska J, Foretova L, Dabek J, Zaridze D, Szeszenia-Dabrowska N, Rudnai P, Fabianova E, Cassidy A, Mates D, Bencko V, Janout V, Hung RJ, Brennan P, Boffetta P. Family history and lung cancer risk: international multicentre case-control study in Eastern and Central Europe and meta-analyses. *Cancer Causes Control* 2010;21:1091-104.

**Llovet et al 1999**

Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. *Semin Liver Dis*. 1999;19(3):329-38.

**Llovet et al 2016**

Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. *Nat Rev Dis Primers*. 2016 Apr 14;2:16018.

**Mak et al 2018**

Mak LY, Cruz-Ramon V, Chinchilla-Lopez P, Torres HA, LoConte NK, Rice JP, et al. Global epidemiology, prevention, and management of hepatocellular carcinoma. *Am Soc Clin Oncol Educ Book* 2018;38:262-79.

**Mäkitaro et al 2002**

Mäkitaro R, Pääkko P, Huhti E, Bloigu R, Kinnula VL. Prospective population-based study on the survival of patients with lung cancer. *Eur Respir J*. 2002;19:1087-92.

**Mallick et al 2013**

Mallick R, Cai J, Wogen J. Predictors of non-adherence to systemic oral therapy for advanced hepatocellular carcinoma. *Curr Med Res Opin.* 2013 Dec;29(12):1701-8.

**Marcano-Bonilla et al 2016**

Marcano-Bonilla L, Mohamed EA, Mounajjed T, Roberts LR. Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations. *Chin Clin Oncol.* 2016;5(5):61.

**Massarweh and El-Serag 2017**

Massarweh NN, El-Serag HB. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. *Cancer Control.* 2017 Jul-Sep;24(3):1073274817729245.

**Maxwell et al 2016**

Maxwell AW, Healey TT, Dupuy DE. Percutaneous Thermal Ablation for Small-Cell Lung Cancer: Initial Experience with Ten Tumors in Nine Patients. *J Vasc Interv Radiol.* 2016;27:1815-1821.

**Mazon R et al 2010**

Mazon R, Etienne-Mastroianni B, Pérol D. Predictive factors of late radiation fibrosis: a prospective study in non-small cell lung cancer. *Int J Radiat Oncol Biol Phys* 2010;77:38.

**McGlynn et al 2015**

McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. *Clin Liver Dis* 2015;19(2):223-38.

**Mohammed et al 2021**

Mohammed S, Polymeros K, Wickham-Joseph R, Luqman I, Charadva C, Morris T, et al. Comparing characteristics of endometrial cancer in women of south Asian and white ethnicity in England. *Cancers.* 2021;13(23):6123.

**Mirsoian and Murphy 2015**

Mirsoian A, Murphy W. Obesity and cancer immunotherapy toxicity. *Immunotherapy* 2015;7(4):319–322. doi:10.2217/imt.15.12

**Nagino et al 2021 [Japanese BTC Treatment Guidelines 2019]**

Nagino M, Hirano S, Yoshitomi H, Aoki T, Uesaka K, Unno M, et al. Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition. *J Hepatobiliary Pancreatic Sci.* 2021;28(1):26-54.

**Naidoo et al 2015**

Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. *Ann Oncol* 2015;26:2375-91.

### **NCCN 2018**

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. Version 6.2018. Available from URL: [https://www.nccn.org/professionals/physician\\_gls/recently\\_updated.aspx](https://www.nccn.org/professionals/physician_gls/recently_updated.aspx). Accessed on: 08 July 2019.

### **NCCN 2019**

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Small cell lung cancer. Version 2.2019. Available from URL: [https://www.nccn.org/professionals/physician\\_gls/recently\\_updated.aspx](https://www.nccn.org/professionals/physician_gls/recently_updated.aspx). Accessed on 08 July 2019.

### **NCCN 2021a**

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers V.5.2021. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/hepatobiliary.pdf](https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf). Accessed on 10 February 2021.

### **NCCN 2021b**

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 6.2021. Available at: [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl\\_blocks.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf). Accessed on 04 November 2021.

### **NCCN 2021c**

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gallbladder and Bile Duct Cancers, Hepatobiliary Cancers. Version 3.2021. Available at: <https://www.nccn.org/patients/guidelines/content/PDF/gallandbile-hp-patient.pdf>. Accessed on 17 February 2021.

### **NCCN 2023**

National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: uterine neoplasms. Version 1.2023. Available from URL: [https://www.nccn.org/professionals/physician\\_gls/pdf/uterine.pdf](https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf)

### **Newsome et al 2018**

Newsome JR, Venkatramani R, Heczey A, Danysh HE, Fishman DS, Miloh T. Cholangiocarcinoma Among Children and Adolescents: A Review of the Literature and Surveillance, Epidemiology, and End Results Program Database Analysis. *J Pediatr Gastroenterol Nutr* 2018;66(1):e12-e18.q

**Nicholas et al 2014**

Nicholas Z, Hu N, Ying J, Soisson P, Dodson M, Gaffney DK. Impact of comorbid conditions on survival in endometrial cancer. *Am J Clin Oncol*. 2014;37(2):131-4.

**Nilsson et al 2017**

Nilsson J, Berglund A, Bergström S. The role of comorbidity in the management and prognosis in non small cell lung cancer: a population-based study. *Acta Oncol* 2017;56:949-56.

**Nishikawa et al 2013**

Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for hepatocellular carcinoma in elderly patients: a literature review. *J Cancer*. 2013 Sep 14;4(8):635-43.

**Nuttall et al 2008**

Nuttall JJ, Davies MA, Hussey GD, Eley BS. Bacillus Calmette-Guérin (BCG) vaccine induced complications in children treated with highly active antiretroviral therapy. *Int J Infect Dis* 2008;12:99-105.

**Oaknin et al 2022**

Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F, et al. Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. *Ann Oncol*. 2022;33(9):860-77.

**Oberli et al 2016**

Oberli LS, Valeri F, Korol D, Rohrman S, Dehler S. 31 years of lung cancer in the canton of Zurich, Switzerland: incidence trends by sex, histology and laterality. *Swiss Med Wkly* 2016;146:w14327.

**Oneda et al 2020**

Oneda E, Abu Hilal M, Zaniboni A. Biliary Tract Cancer: Current Medical Treatment Strategies. *Cancers (Basel)*. 2020;12(5):1237.

**Patel 2011**

Patel T. Cholangiocarcinoma—controversies and challenges. *Nat Rev Gastroenterol Hepatol*. 2011;8(4):189–200.

**Raglan et al 2019**

Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J, et al. Risk factors for endometrial cancer: An umbrella review of the literature. *Int J Cancer*. 2019;145(7):1719-30.

**Reeves et al 2016**

Reeves HL, Zaki MY, Day CP. Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. *Dig Dis Sci*. 2016 May;61(5):1234-45.

**Riaz et al 2012**

Riaz SP, Lüchtenborg M, Coupland VH, Spicer J, Peake MD, Møller H. Trends in incidence of small cell lung cancer and all lung cancer. *Lung Cancer* 2012;75:280-4.

**Rodrigues et al 2004**

Rodrigues G, Lock M, D'Souza DD, Yu E, Van Dyk J. Prediction of radiation pneumonitis by dose volume histogram parameters in lung cancer – a systemic review. *Radiotherapy and Oncology* 2004;71:127-38.

**Rossetto et al 2010**

Rossetto A, Bitetto D, Bresadola V, Lorenzin D, Baccarani U, De Anna D, et al. Cardiovascular risk factors and immunosuppressive regimen after liver transplantation. *Transplant Proc.* 2010 Sep;42(7):2576-8.

**Rowell and O'Rourke 2004**

Rowell NP, O'Rourke N. Concurrent chemoradiotherapy in non-small cell lung cancer (Review). *The Cochrane Collaboration.* John Wiley & Sons, Ltd. 2004; Issue 4. Available from: URL: <http://www.thecochranelibrary.com>.

**Sarveazad et al 2019**

Sarveazad A, Agah S, Babahajian A, Amini N, Bahardoust M. Predictors of 5-year survival rate in hepatocellular carcinoma patients. *J Res Med Sci.* 2019 Oct 25;24:86.

**Sasaki et al 2021**

Sasaki T, Takeda T, Okamoto T, Ozaka M, Sasahira N. Chemotherapy for Biliary Tract Cancer in 2021. *J. Clin. Med.* 2021;10: 3108.

**SEER Program [Data Period 2008 to 2018]**

National Cancer Institute. About the SEER Program. SEER. <https://seer.cancer.gov/about/overview.html>.

**Setiawan et al 2007**

Setiawan VW, Pike MC, Kolonel LN, Nomura AM, Goodman MT, Henderson BE. Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort study. *Am J Epidemiol.* 2007 Feb;165(3):262-70.

**Siegel et al 2017**

Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin* 2017;67:7-30.

**Siegel et al 2023**

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. *CA Cancer J Clin* 2023;73(1):17-48.

**Spina et al 2013**

Spina R, Chu SYY, Chatfield M, Chen J, Tin MM, Boyer M. Outcomes of chemoradiation for patients with locally advanced non-small-cell lung cancer. *Intern Med J* 2013;43790-7.

**Straif et al 2009**

Straif K, Benbrahim-Tallaa L, Baan R, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens--Part C: metals, arsenic, dusts, and fibres. *Lancet Oncol* 2009;10:453-4.

**Sung et al 2021**

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2021;71:209-49.

**Taglauer et al 2009**

Taglauer ES, Yankee TM, Petroff MG. Maternal PD-1 regulates accumulation of fetal antigen-specific CD8+ T cells in pregnancy. *J Reprod Immunol* 2009;80:12-21.

**Takahara et al 2020**

Takahara N, Nakai Y, Saito K, Sasaki T, Suzuki Y, Inokuma A, et al. The impact of age and comorbidity in advanced or recurrent biliary tract cancer receiving palliative chemotherapy. *J Gastroenterol Hepatol*. 2020 Oct;35(10):1828-1835.

**Takahashi et al 2013**

Takahashi R, Yoshitomi M, Yutani S, Shirahama T, Noguchi M, Yamada A, et al. Current status of immunotherapy for the treatment of biliary tract cancer. *Hum Vaccin Immunother*. 2013;9(5):1069-72.

**Tinkle and Haas-Kogan 2012**

Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. *Biologics*. 2012;6:207-19.

**Tsilimigras et al 2020**

Tsilimigras DI, Sahara K, Wu L, Moris D, Bagante F, Guglielmi A, et al. Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches. *JAMA Surg*. 2020;155(9):823-31.

**Turkes et al 2019**

Turkes F, Carmichael J, Cunninham D, Starling N. Contemporary tailored oncology treatment of biliary tract cancers. *Gastroenterol Res Pract*. 2019;2019:7698786.

**Valle et al 2016**

Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D, et al. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2016;27(suppl 5):v28-37.

**Valle et al 2017**

Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New Horizons for Precision Medicine in Biliary Tract Cancers. *Cancer Discov.* 2017 Sep;7(9):943-62.

**Valle et al 2021**

Valle JW, Kelley KR, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. *Lancet.* 2021;397:428-44.

**Villanueva 2019**

Villanueva A. Hepatocellular Carcinoma. *N Engl J Med.* 2019 Apr 11;380(15):1450-1462.

**Vogel et al 2018**

Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2018 Oct 1;29(Suppl 4):iv238-iv255. Erratum in: *Ann Oncol.* 2019 May 1;30(5):871-873. Erratum in: *Ann Oncol.* 2019 May;30(5):871-873.

**Vogel et al 2021**

Vogel A, Bathon M, Saborowski A. Immunotherapies in clinical development for biliary tract cancer. *Expert Opin Investig Drugs.* 2021;30(4):351-63.

**Vogel and Martinelli 2021**

Vogel A, Martinelli E, on behalf of the ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. *Ann Oncol* 2021;32(6):801-5.

**Walter et al 2015**

Walter FM, Rubin G, Bankhead C, Morris HC, Hall N, Mills K, Dobson C, Rintoul RC, Hamilton W, Emery J. Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort study. *Br J Cancer* 2015;112 Suppl 1:S6-13.

**Wang et al 2012**

Wang S, Wong ML, Hamilton N, Davoren JB, Jahan TM, Walter LC, et al. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. *J Clin Oncol* 2012;30:1447-55.

**Wang et al 2017**

Wang S, Tang J, Sun T, Zheng X, Li J, Sun H, Zhou X, Zhou C, Zhang H, Cheng Z, Ma H, Sun H. Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages. *Sci Rep* 2017;7:1339.



**Wang et al 2020a**

Wang H, Sun P and Baria K. The world-wide incidence of biliary tract cancer [poster]. Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology. 2020, Jan 23-25; San Francisco; 585.

**Wang et al 2020b**

Wang H, Binbing Y, Sun P, Baria K. Biliary tract cancer (BTC epidemiology in the United States. International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE). 2020, Sep 16–17; Virtual Meeting.

**White et al 2017**

White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. *Gastroenterology* 2017;152:812-820, e5.

**WHO 2019**

World Health Organization. Global Cancer Observatory. Cancer Fact Sheets – Liver and intrahepatic bile ducts (C22). Available at URL:  
<http://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf>

**WHO 2020**

World Health Organization. Global Cancer Observatory. Cancer Fact Sheets – Liver and intrahepatic bile ducts (C22). Available at URL:  
<http://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf>

**Yachimski and Pratt 2008**

Yachimski P, Pratt DS. Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. *J Clin Gastroenterol.* 2008 Feb;42(2):178-90.

**Yavas and Yavas 2017**

Yavas G and Yavas C. Radiation Therapy in the Treatment of Small Cell Lung Cancer. *Ann Lung Cancer* 2017;1:15-24.

**VII: PART VII: ANNEXES**

[Annex 4](#) [Specific Adverse Drug Reaction Follow-Up Forms](#) (*Not applicable*)

[Annex 6](#) [Details of Proposed Additional Risk Minimisation Activities](#) (*Not applicable*)

**Annex 4: Specific Adverse Drug Reaction Follow-Up Forms (Not Applicable)**

Not applicable.

**Annex 6: Details of Proposed Additional Risk Minimisation Activities  
(Not Applicable)**

Not applicable.